

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, 14/705, 7/06, 16/18, A61K 31/70, 38/08, 35/14, 38/17, G01N 33/53		A2	(11) International Publication Number: WO 00/32769 (43) International Publication Date: 8 June 2000 (08.06.00)
 (21) International Application Number: PCT/IB99/02018 (22) International Filing Date: 26 November 1999 (26.11.99) (30) Priority Data: 9826143.1 27 November 1998 (27.11.98) GB		 (74) Agents: WOODWARD, John, Calvin et al.; Venner, Shipley & Co., 20 Little Britain, London EC1A 7DH (GB). (81) Designated States: AU, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
 (71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [US/US]; 605 Third Avenue, New York, NY 10158 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): HUANG, Lan-Qing (BE/BE); Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). VAN PEL, Aline (BE/BE); Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). BRASSEUR, Francis (BE/BE); Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). DE PLAEN, Etienne (BE/BE); Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). BOON, Thierry (BE/BE); Ludwig Institute for Cancer Research, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE).			
 (54) Title: TUMOUR REJECTION ANTIGENS (57) Abstract Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Tumour rejection antigens

Description

This invention relates to polypeptides and proteins expressed in tumour cells and to nucleic acid molecules coding for such polypeptides and proteins. The invention also relates to expression vectors and host cells for expressing such polypeptides and proteins, and to polypeptide-binding agents which selectively bind or are specific for such polypeptides or proteins. The invention further relates to methods of treating and diagnosing disease, preferably cancers, using such polypeptides, proteins, nucleic acids, polypeptide-binding agents, expression vectors or transformed host cells.

The phenotypic changes which distinguish a tumour cell from its normal counterpart are often the result of one or more changes to the genome of the cell.

The genes which are expressed in tumour cells, but not in normal counterparts, can be termed "tumour specific" or "tumour associated" genes. These tumour specific or associated genes can be markers for the tumour phenotype.

The process by which the mammalian immune system recognises and reacts to foreign or alien materials is a complex one. An important facet of the system is the response of cytolytic T lymphocytes (CTLs) or T cells. CTLs recognise and interact with complexes of cell surface molecules, referred to as human leukocyte antigens ("HLA"), or major histocompatibility complex molecules ("MHC" molecules), and other peptides derived from larger molecules from within the cells carrying the HLA/MHC complexes. See, in this regard, Male et al., Advanced Immunology (J.P. Lipincott Company, 1987), especially chapters 6-10, and C.A. Janeway et al. Immuno Biology third ed. (Current Biology Ltd. 1997). The interaction of T cells and complexes of HLA/peptide is restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific CTL is not present, there is no T cell response even if its partner complex is present. Similarly, there is no response if the specific complex is absent, but the CTL is present. The mechanism is involved in the immune system's response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities. Much work has

focused on the mechanisms by which proteins are processed into the HLA binding peptides. See, in this regard, Barinaga, *Science* 257:880, 1992; Fremont et al., *Science* 257:919, 1992; Matsumura et al., *Science* 257:927, 1992; Latron et al., *Science* 257: 964, 1992.

5

- The mechanism by which T cells recognise cellular abnormalities has also been implicated in cancer. A number of families of genes which are processed into peptides that are presented as HLA/peptide complexes on the surface of tumour cells, with the result that the cells can be lysed by specific CTLs, have been discovered. These genes are said to code for "tumour rejection antigen precursors" or "TRAP" molecules, and the peptides derived therefrom that complex with HLA are referred to as "tumour rejection antigens" or "TRAs". Intensive efforts have been made in this field and a wealth of human tumour rejection antigens (both TRAPs and TRAs) which are recognised by T cells have been identified (Van den Eynde, B.J., and P. van der Bruggen, 1997, *Curr. Opin. Immunol.* 9:684.). Among them, a TRAP encoded by the gene *MAGE-1* was initially defined by cultivating blood lymphocytes of patient MZ2 in the presence of a melanoma cell line derived from the same patient. A panel of CTL clones was generated by mixed lymphocyte-tumour cell culture (MLTC) techniques, and one of these clones recognised a nonapeptide TRA derived from the *MAGE-1* TRAP, which is presented by HLA-A1 (van der Bruggen, P., C. et al., 1991, *Science (Wash. DC)*, 254:1643-1647; Traversari, C., et al., 1992, *J. Exp. Med.* 176:1453-1457 and WO92/20356). It was found later that *MAGE-1* belongs to a family of at least seventeen related genes, namely *MAGE-1* to -12 (now named *MAGE-A1* to -*A12*) (De Plaen, E., et al., 1994, *Immunogenetics*, 40:360-369.), *MAGE-B1* to -*B4* (Muscatelli, F., et al., 1995, *Proc. Natl. Acad. Sci. USA*, 92:4987-4991; Dabovic, B., et al., 1995, *Mammalian Genome*, 6:571-580; and Lurquin, C., et al., 1997, *Genomics*, 46:397-408), and *MAGE-C1* (Lucas, S., et al., 1998, *Cancer Res.* 58:743-752).
- Genes of this family are expressed in various tumours of different histological types, but are completely silent in normal tissues with the exception of testis and placenta (De Plaen, E., et al., 1994, *Immunogenetics*, 40:360-369; Dabovic, B., et al., 1995, *Mammalian Genome*, 6:571-580; Lurquin, C., et al., 1997, *Genomics*, 46:397-408; and

Lucas, S., et al., 1998, *Cancer Res.* 58:743-752.). However, as testicular germ cells and placental trophoblasts do not express MHC class 1 molecules (Haas, G.G.Jr., et al., 1988, *Am. J. Reprod. Immunol. Microbiol.* 18:47-51.), gene expression in these tissues should not lead to antigen expression. Indeed, immunisation of male mice 5 with an antigen encoded by mouse P1A gene, which has the same expression pattern as human *MAGE* gene, i.e., expressed in tumours, testis and placenta, but silent in other normal tissues, produced strong P1A-specific CTL responses that did not cause testis inflammation or alteration of fertility (Uyttenhove, C., C. et al., 1997, *Int. J. Cancer.* 70:349-356.). Antigens encoded by *MAGE* genes are, therefore, 10 suitable candidates for vaccine-based immunotherapy of cancers and as markers for providing a means of identifying a cell as a so treatable tumour cell.

So far, however, it has only proven possible to identify TRAs encoded by *MAGE-A1*, -*A3* and -*A6* by using autologous CTLs derived from mixed lymphocyte-tumour cell cultures (MLTC) and previous gene expression assays have suggested 15 that *MAGE-A10* was expressed in tumours at a level that was too low to be sufficient for CTL recognition. All these CTLs were generated from only one patient, MZ2 (Traversari, C., et al., 1992, *J. Exp. Med.* 176:1453-1457; van der Bruggen, P., et al., 1994, *Eur. J. Immunol.* 24:2134-2140; Gaugler, B., et al., 1994, 20 *Exp. Med.* 179:921-930; De Plaen, E., et al., 1994, *Immunogenetics.* 40:360-369; and P. van der Bruggen, unpublished data). However, the inventors have now been able to obtain autologous CTL clones from another melanoma patient, LB 1751, which recognize and have allowed the identification of hitherto unknown HLA-A2.1-presented TRAs encoded by *MAGE-A10* and *MAGE-A8*.

25

Accordingly, the present invention provides a polypeptide comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 (Figure 7) or SEQ. ID. NO. 2 (Figure 8) which has an ability to complex with an MHC molecule type HLA-A2, preferably HLA-A2.1. Polypeptides in accordance with the invention can comprise 30 unbroken sequences of amino acids from SEQ. ID. NO. 1 or 2 which have an ability to elicit an immune response from human lymphocytes.

Polypeptides in accordance with the invention can comprise nonapeptides having an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2, wherein the amino acid adjacent to the N-terminal amino acid is L or M, preferably L, and the C-terminal amino acid is L, V or I, preferably L. Preferably, the amino acid in position 3 is Y, and/or the amino acid in position 4 is D, and/or the amino acid in position 5 is G, and/or the amino acid in position 7 is E, and/or the amino acid in position 8 is H. The amino acid positions are numbered from the N-terminal to the C-terminal, with the N-terminal amino acid in position 1. The polypeptides described above are preferably capable of complexing with a MHC molecule type 10 HLA-A2, and preferably HLA-A2.1.

The invention, preferably, does not encompass nonapeptides having the amino acid sequences FLLFKYQMK (SEQ. ID. NO. 48), FIEGYCTPE (SEQ. ID. NO. 49), and GLELAQAPL (SEQ. ID. NO. 50).

15 The inventive polypeptide alternatively can be a decapeptide comprising a nonapeptide as defined above and, preferably, an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2. In preferred embodiments the nonapeptide has the amino acid sequence GLYDGMEHL (SEQ. ID. NO. 42) or GLYDGREHS (SEQ. ID. NO. 43), preferably GLYDGMEHL (SEQ. ID. NO. 42). In embodiments, the decapeptide can have the amino acid sequence GLYDGMEHLI (SEQ. ID. NO. 44) or GLYDGREHSV (SEQ. ID. NO. 45), preferably GLYDGMEHLI (SEQ. ID. NO. 44).

25 In a further aspect, the present invention comprises a polypeptide or protein of up to about 93 amino acids in length which comprises a nonapeptide or a decapeptide as defined above. Such a polypeptide or protein can comprise or consist of an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2, preferably SEQ. ID. NO. 1.

30 It is preferred that polypeptides in accordance with the present invention are capable of eliciting an immune response from human lymphocytes, preferably when complexed with an MHC molecule type HLA-A2, preferably HLA-A2.1. The

immune response is preferably a cytolytic response from human T-lymphocytes, preferably CD8 T-cells.

In a further aspect, the present invention provides a polypeptide or protein comprising a polypeptide as defined above, wherein the amino acid sequence of said polypeptide or protein is not either of the complete sequences set out in SEQ. ID. NOs. 1 and 2, or that coded for by nucleotides 334-918 of SEQ. ID. NO. 7 (Figure 13).

The invention also extends to polypeptides or proteins which are functionally equivalent homologues to any of the above defined polypeptides or proteins, but with the proviso that the amino acid sequence of said polypeptide or protein is not an entire sequence as set out in either of SEQ. ID. NOs. 1 and 2, or that coded for by nucleotides 334-918 of SEQ. ID. No. 7. In embodiments of the invention, the polypeptides can be complexed with an MHC molecule type HLA-A2, preferably HLA-A2.1.

In another aspect, the present invention provides nucleic acid molecules, each comprising a nucleotide sequence coding for a polypeptide or protein in accordance with previously defined aspects of the invention or a complimentary nucleotide sequence, wherein said nucleotide sequence is not an entire sequence as set out in any of SEQ. ID. NO. 3 (Figure 9), SEQ. ID. NO. 4 (Figures 10a and 10b), SEQ. ID. NO. 5 (Figures 11a and 11b), SEQ. ID. NO. 6 (Figure 12) and SEQ. ID. NO. 7 (Figure 13). Such a nucleic acid molecule can comprise an unbroken sequence of nucleotides from SEQ. ID. NO. 3, 4 or 5, or a complimentary sequence, or an RNA transcript of said nucleic acid molecule.

In a preferred embodiment, such a nucleic acid molecule can encode a plurality of epitopes or a polytope.

In a further aspect, the present invention provides expression vectors, each comprising a nucleic acid molecule as previously defined, operably linked to a promoter. Expression vectors in accordance with the invention can comprise a

nucleotide sequence coding for an MHC molecule type HLA-A2, preferably HLA-A2.1, a cytokine or a co-stimulatory molecule, or a bacterial or viral genome or a portion thereof.

- 5 In an additional aspect, the present invention relates to host cells, each transformed or transfected with an expression vector in accordance with the invention. Such a host cell can be transformed or transfected with an expression vector coding for an MHC molecule type HLA-A2, preferably HLA-A2.1, and/or a cytokine or a co-stimulatory molecule.

10

- In a yet further aspect, the present invention provides polypeptide-binding agents, each of which can selectively bind or is specific for an isolated polypeptide or protein in accordance with the invention. A polypeptide-binding agent in accordance with the invention can comprise an antibody, preferably a monoclonal antibody or an antibody fragment specific for an isolated polypeptide in accordance with the invention. Preferably, such polypeptide-binding agents can selectively bind or are specific for a complex of a polypeptide in accordance with the invention and an MHC molecule type HLA-A2, preferably HLA-A2.1, but do not bind said major histocompatibility molecule alone. Further polypeptide-binding agents in accordance with the invention include CTLs and CTL clones which recognise and selectively lyse cells which carry a polypeptide in accordance with the invention complexed with an MHC molecule type HLA-A2, preferably HLA-A2.1.

- 25 In another aspect, the present invention relates to the use of a polypeptide or protein, isolated nucleic acid molecule, expression vector, host cell, or polypeptide-binding agent in accordance with the invention, in the therapy, prophylaxis, or diagnosis of disease and, preferably, of tumours. Thus, the invention also relates to pharmaceutical compositions for the prophylaxis, therapy or diagnosis of disease, preferably of tumours, comprising a polypeptide or protein, a nucleic acid molecule, an expression vector, a host cell, or a polypeptide-binding agent in accordance with the invention, optionally in admixture with a pharmaceutically acceptable carrier and optionally further comprising a major histocompatibility molecule type HLA-A2, preferably HLA-A2.1. Such pharmaceutical compositions can be employed as anti-

tumour vaccines. Optionally pharmaceutical compositions in accordance with the invention can include other TRAs or TRAPs, expression vectors or host cells expressing other TRAs or TRAPs, or polypeptide-binding agents specific for other TRAs or TRAPs. In another embodiment, pharmaceutical compositions in accordance with the invention can further comprise a co-stimulatory molecule.

In a preferred embodiment, a pharmaceutical composition in accordance with the invention comprises an antigen presenting cell (APC), preferably a dendritic cell, which has been pulsed with a polypeptide in accordance with the invention so as to present on its surface said peptide as a complex with a major histocompatibility molecule, HLA.

In another aspect, the present invention provides peptide-pulsed antigen presenting cells.

In a yet further aspect, the invention relates to a method of diagnosing disease, preferably cancer, comprising contacting a biological sample isolated from a subject with an agent that is specific for a polypeptide or protein in accordance with the invention, or a nucleic acid molecule in accordance with the invention and assaying for interaction between the agent and any of the polypeptide, protein or nucleic acid molecule in the sample as a determination of the disease. The polypeptide-binding agent employed in this aspect of the invention can be a polypeptide-binding agent in accordance with a previously described aspect of the invention.

The invention also relates to methods of producing cytolytic T-cell cultures reactive against tumour cells. Such a method can comprise steps of removing a lymphocyte sample from an individual and then culturing the lymphocyte sample with a polypeptide or protein in accordance with the invention, an expression vector in accordance with the invention, or a host cell in accordance with the invention. Products comprising cytolytic T-cells reactive against a tumour cell expressing an antigen comprising a polypeptide or protein in accordance with the invention, can be used in the prophylaxis, therapy or diagnosis of disease preferably of tumours,

are also encompassed in the present invention, particularly when obtained or obtainable by the aforementioned method.

As set out above, the present invention can involve the use of expression vectors to transform or transfect host cells and cell lines. Thus, a coding DNA sequence in accordance with the invention can be introduced into an expression vector suitable for directing expression of a polypeptide or protein in accordance with the invention (coded for by that DNA sequence) in a host cell. Suitable vectors include bacterial plasmids, phage DNA, cosmids, yeast plasmids and viral DNA, such as pox virus (e.g. vaccinia), retrovirus, baculovirus and adenovirus DNA. The procedure generally involves inserting a DNA sequence to be expressed into an appropriate restriction endonuclease site so that it is operably linked to a promoter for directing mRNA synthesis. A coding sequence and regulatory sequence, such as a promoter sequence, are considered to be "operably" linked when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequence. The resulting vector may then be employed to transform or transfect an appropriate host cell to cause that host cell to express the required polypeptide or protein. Appropriate host cells can be higher eukaryotic cells, such as mammalian cells and insect cells or can be lower eukaryotic cells, such as yeast cells, or prokaryotic cells, such as bacterial cells. Examples include E-coli, Bowes melanoma, CHO and COS cells. Selection of an appropriate host and the manner in which the vector is introduced into the host cell are matters within the knowledge of those skilled in the art. However appropriate techniques, cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described in Sambrook et al, Molecular Cloning, A Laboratory Manual, Second edition, ColdSpring Harbour, NY, 1989.

Expression vectors in accordance with the invention can include a nucleic acid sequence coding for the HLA molecule that presents a particular polypeptide in accordance with the invention. Alternatively, the nucleic acid sequence coding for the HLA molecule can be contained within a separate expression vector within a host cell in accordance with the invention. In a situation where the vector contains both coding sequences, the single vector can be used to transfet the cell which

does not normally express either one. Where the coding sequence for the inventive polypeptide or protein and the HLA molecule which presents the former are contained on separate expression vectors, the expression vectors can be cotransfected. Sequences coding for polypeptides or proteins in accordance with 5 the invention may be used alone, when, e.g. the host cell already expresses an HLA molecule which presents the TRA.

Preferred systems for mRNA expression in mammalian cells include the pRc/CMV (available from Invitrogen, Carlsbad, CA, USA) system that contains a selectable 10 marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cells lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy 15 extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (Nuc. Acids Res. 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (Mol. Cell. Biol. 16:4710-4716, 1996). A further 20 preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (J. Clin. Invest. 90:626-630, 1992). The use of the adenovirus as an adeno-P1A recombinant is disclosed by Warnier et al: in Intradermal injection in mice for immunisation against P1A (Int. J. Cancer, 67:303-310, 1996).

25

As stated above, the invention can involve polypeptide-binding agents specific for or selective for polypeptides or proteins in accordance with the invention. An agent should be considered as "specific" for a particular polypeptide or protein if it is capable of interacting with that polypeptide or protein in a manner which can be 30 distinguished from its interaction with other molecules in the context in which it is used. For example, such an agent may be capable of selectively binding to a relevant polypeptide or protein under the conditions prevalent in a particular assay. The term "contacting" means that a biological sample is placed in sufficient

proximity to an agent and under appropriate conditions of, for example, concentration, temperature, time, to allow the specific interaction between the agent and any polypeptide or protein for which it is specific, to take place. Appropriate conditions for contacting agents and biological samples are well known to those skilled in the art and are selected to facilitate the specific interaction between particular target molecules and specific agents. Polypeptide-binding agents can be used in this way in screening assays to detect the presence or absence of proteins or polypeptides in accordance with the invention and in purification protocols to isolate such proteins and polypeptides. Polypeptide-binding agents in accordance with the invention can be in the form of immobilised antibodies attached to a substrate and the inventive method of diagnosing disease can involve a conventional enzyme-linked immunosorbent assay (ELISA) carried out on a protein containing biological sample derived from a patient. Alternatively, the method can comprise a Western blot in which the agent is a labelled antibody and the biological sample comprises proteins derived from a patient and separated by electrophoresis on an SDS polyacrylamide gel. Polypeptide-binding agents can be used to selectively target drugs, toxins or other molecules to cancer cells which present polypeptides in accordance with the invention. In this manner, cells present in tumours which express polypeptides or proteins in accordance with the invention can be treated with cytotoxic compounds.

As stated, the invention can involve antibodies or fragment of antibodies having the ability to selectively bind to polypeptides or proteins in accordance with the invention. Such antibodies include polyclonal and monoclonal antibodies, prepared according to the conventional methodology.

The antibodies of the present invention can be prepared by any of a variety of methods, including administering protein, fragments of protein, cells expressing the protein or fragments thereof and the like to an animal to induce polyclonal antibodies. The production of monoclonal antibodies is according to techniques well known in the art. Such antibodies may be used for example to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific labelling agents for imaging or to antitumour agents, including, but not limited to,

methotrexate, radioiodinated compounds, toxins such as ricin, other cystostatic or cytolytic drugs, and so forth. Antibodies prepared according to the invention also preferably are specific for the TRA/HLA complexes described herein.

5 Significantly, as is well known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark W.R. (1986) *The Experimental Foundations of Modern Immunology* Wiley & Sons, Inc., New York; Roitt, I. (1991) *Essential Immunology*, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for
10 example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')₂ fragment, retains both of the antigen binding sites of an intact antibody. Similarly,
15 an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.
20

Within the antigen-binding portion of an antibody, as is well known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complimentarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.
25
30

It is now well established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of nonspecific or heterospecific antibodies while retaining the epitope specificity of the original antibody. This is most clearly manifested in the development and use of "humanised" antibodies which non-human CDRs are covalently joined to human FR and/or Fc/Fc' regions to produce a functional antibody. Thus, for example, PCT International Publication Number WO92/04381 teaches the production and use of humanised murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for $F(ab')_2$, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric $F(ab')_2$ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies. Thus, the invention can involve polypeptides of numerous sizes and types that bind specifically or selectively to polypeptides and proteins in accordance with the invention. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilised form or as phage display libraries. Combinatorial libraries can also be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent a completely degenerate or 5 biased array. One can then select phage-bearing inserts which bind to a polypeptide or protein in accordance with the invention. This process can be repeated through several cycles of reselection of phage that bind to a polypeptide or protein in accordance with the invention. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify 10 the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to a polypeptide or protein in accordance with the invention can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Thus, a 15 polypeptide or protein in accordance with the invention can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the polypeptides of the invention. Such molecules can be used, as described, for screening assays, for diagnostic assays, for purification protocols or for targeting drugs, toxins and/or labelling agents (e.g. radioisotopes, fluorescent 20 molecules, etc.) to cells which express a polypeptide or protein in accordance with the invention on the cell surface. Such binding agent molecules can also be prepared to bind complexes of a polypeptide or protein in accordance with the invention and an HLA molecule by selecting the binding agent using such complexes. Drug molecules that would disable or destroy tumour cells which 25 express such complexes are known to those skilled in the art and are commercially available. For example, the immunotoxin art provides examples of toxins which are effective when delivered to a cell by an antibody or fragment thereof. Examples of toxins include ribosome-damaging toxins derived from plant or bacterial such as ricin, abrin, saporin, Pseudomomonas endotoxin, diphtheria toxin, A chain toxins, 30 blocked ricin, etc.

The invention as described herein has a number of uses, some of which are described herein. First the invention permits the diagnosis of a disorder

characterised by an expression of a polypeptide or protein in accordance with the invention. The methods can involve determining expression of the gene coding for a polypeptide or protein in accordance with the invention. In the former situation, such determinations can be carried out by any standard nucleic acid determination assay, including the polymerase chain reaction or assaying with labelled hybridisation probes, while in the latter situation, assaying with polypeptide-binding agents in accordance with the invention, such as antibodies, is preferred. An alternative method for determination is an assay for recognition of a TRA/HLA complex by a peptide-specific CTL by assaying for CTL activity. Such assays include 5 a TNF release assay, of the type described below, a chromium release assay or a technique called ELISPOT in which CTL activity can be detected via antibody detection of IFN- γ or TNF α release (Schmittel et al (1997). J. Immunol. Methods 10 210:167-174 and Lalvani et al. J. Exp. Med. 186:859-865 (1997)).

15 Other TRAPs or TRAs recognised by the CTL clones described herein may be isolated by the procedures detailed herein.

A variety of methodologies well known to the skilled practitioner can be utilised to obtain isolated TRA and TRAP molecules such as those which are the subject of the 20 present invention. The protein may be purified from cells which naturally produce the protein. Alternatively, an expression vector may be introduced into cells to cause production of the protein. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause the production of the encoded protein. Translation of mRNA in cell-free extracts such as reticulocyte 25 lysate system also may be used to produce protein. Peptides comprising TRAs of the invention may also be synthesised *in vitro*. Those skilled in the art can also readily follow known methods for isolating proteins in order to obtain isolated TRAPs and/or TRAs derived therefrom. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

Polypeptides or proteins in accordance with the invention or complexes thereof with HLA, again in accordance with the invention, may be combined with materials

such as adjuvants to produce vaccines useful in treating disorders characterised by expression of a polypeptide or protein in accordance with the invention.

Certain therapeutic approaches based upon the disclosure are premised on a response by the subject's immune system, leading to lysis of TRA presenting cells. One such approach is the administration of autologous CTLs specific to the complex to a subject with abnormal cells of the phenotype at issue. It is within the skill of the artisan to develop such CTLs *in vitro*. Generally, a sample of cells taken from a subject, such as blood cells, are contacted with a cell presenting the complex and capable of provoking CTLs to proliferate. The target cell can be a transfectant, such as a COS cell. These transfectants present the desired complex on their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells, such as those used herein are widely available, as are other suitable host cells. Specific production of a CTL is well known to one of ordinary skill in the art. One method for selecting antigen-specific CTL clones has recently been described (Altman et al., Science 274:94-96, 1996; Dunbar et al., Curr. Biol. 8:413-416, 1998), in which fluorogenic tetramers of MHC class I molecule/peptide complexes are used to detect specific CTL clones. Briefly, soluble MHC class I molecules are folded *in vitro* in the presence of β_2 -microglobulin and a peptide antigen which binds the class I molecule. After purification, the MHC/peptide complex is purified and labelled with biotin. Tetramers are formed by mixing the biotinylated peptide-MHC complex with labelled avidin (e.g. phycoerythrin) at a molar ratio of 4:1. Tetramers are then contacted with a source of CTLs such as peripheral blood or lymph node. The tetramers bind CTLs which recognise the peptide antigen/MHC class I complex. Cells bound by the tetramers can be sorted by fluorescence activated cell sorting to isolate the reactive CTLs. The isolated CTLs then can be expanded *in vitro*. The clonally expanded autologous CTLs then can be administered to the subject. Other CTLs specific to a polypeptide or protein in accordance with the invention may be isolated and administered by similar methods.

30

To detail a therapeutic methodology, referred to as adoptive transfer (Greenberg. J. Immunol. 136(5):1917, 1986; Riddel et al. Science 257:238, 1992; Lynch et al, Eur. J. Immunol. 21:1403-1410, 1991; Kast et al., Cell 59:603-614, 1989), cells presenting

the desired complex are combined with peripheral blood lymphocytes containing CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterised by certain of the abnormal cells presenting the particular complex. The CTLs then 5 lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/TRA complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular 10 HLA molecule, as well as how to identify cells expressing DNA or protein of the pertinent sequences. In this case, *MAGE-A10* expression could be determined, for example, by conducting a PCR assay using primers from unique parts of the *MAGE-A10* DNA. Alternatively, other well known antibody based techniques can be employed to identify cells presenting a relevant TRA/HLA complex. Once cells 15 presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient containing CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that the TRA is being presented, and the subject is an appropriate candidate for the therapeutic approaches set forth herein.

20 Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked *in vivo*, using a number of approaches.

25 One approach is the use of non-proliferative cells expressing the complex as vaccines. Such vaccines can be prepared from cells, which can be host cells in accordance with the invention, that present TRA/HLA complexes on their surface. The cells used in this approach may be those that normally express the complex, such as irradiated non-proliferative tumour cells or non-proliferative transfectants 30 etcetera. Chen et al., Proc. Natl. Acad. Sci. USA 88:110-114 (1991) exemplifies this approach, showing the use of transfected cells expressing HPV E7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are

especially preferred. For example, nucleic acids which encode a polypeptide or protein in accordance with the invention may be operably linked to promoter and enhancer sequences which direct expression of the polypeptide or protein in accordance with the invention in certain tissues or cell types. The nucleic acid may
5 be incorporated into an expression vector. Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding a polypeptide or protein in accordance with the invention. Nucleic acids encoding a polypeptide or protein in accordance with the invention also may be inserted into a retroviral
10 genome, thereby facilitating integration of the nucleic acid into the genome of the target tissue or cell type. In these systems, the gene of interest is carried by a microorganism, e.g., a vaccinia virus, retrovirus or the bacteria BCG, and the materials *de facto* "infect" host cells. The cells which result present the complex of interest, and are recognised by autologous CTLs, which then proliferate. In all cases
15 where cells are used as a vaccine, these can be cells transfected with coding sequences for one or both of the components necessary to provoke a CTL response, or be cells which already express both molecules without the need for transfection. These cells can also be antigen presenting cells (APCs), such as dendritic cells (DC) which have been "pulsed" with the TRAs of the invention or
20 peptides derived therefrom (Nestle et al. Nat. Med. 4:328-332, 1998; Mukherji et al. Proc. Nat. Acad. Sci. USA. 92:8078-8082, 1995; Hu et al. Cancer Res. 56:2479-2483, 1996).

Vaccines also encompass naked DNA or RNA, encoding a polypeptide or protein in
25 accordance with the invention, which may be produced *in vitro* and administered via injection, particle bombardment, nasal aspiration and other methods. Vaccines of the "naked nucleic acid" type have been demonstrated to provoke an immunological response including generation of CTLs specific for the peptide encoded by the naked nucleic acid (Science 259:1745-1748, 1993). When "disorder" is used herein,
30 it refers to any pathological condition where the tumour rejection antigen precursor is expressed. An example of such a disorder is cancer, particularly melanoma.

A similar effect can be achieved by combining a polypeptide or protein in accordance with the invention with an adjuvant to facilitate incorporation into HLA presenting cells *in vivo*. The polypeptide or protein in accordance with the invention complexes with a molecule which presents the polypeptide or protein in accordance with the invention without the need for further processing. Generally, subjects can receive an intradermal injection of an effective amount of a polypeptide or protein in accordance with the invention. Initial doses can be followed by booster doses, following immunisation protocols standard in the art.

- 10 Especially preferred are nucleic acids encoding a series of epitopes, known as "polytopes". The epitopes can be arranged in sequential or overlapping fashion (see, e.g. Thompson et al, Proc. Natl. Acad. Sci. USA 92:5845-5849, 1995; Gilbert et al, Nature Biotechnol. 15:1280-1284, 1997) with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The 15 polytope is processed to generate individual epitopes which are recognized by the immune system for generation of immune responses.

Thus, for example, peptides in accordance with the invention and which are presented by MHC molecules and recognised by CTL or T helper lymphocytes can 20 be combined with peptides from other tumour rejection antigens (e.g. by preparation of hybrid nucleic acids or polypeptides) to form "polytopes". Exemplary tumour associated peptide antigens that can be administered to induce or enhance an immune response are derived from tumour associated genes and encoded proteins including MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, 25 MAGE-6, MAGE-7, MAGE-8, MAGE-9, MAGE-10, MAGE-11, MAGE-12, MAGE 13, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, BAGE-1, RAGE-1, RAGE-2, RAGE-3, RAGE-4, LB33/MUM-1, DAGE (PRAME), NAG, MAGE-Xp2 (MAGE-B2), MAGE-Xp3, (MAGE-B3), MAGE-Xp4 (MAGE-B4), tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-C1, 30 MAGE-C2, NY-ESO-1, LAGE-1, SSX-1, SSX-2 (HOM-MEL-40), SSX-4, SSX-5, SCP-1 and CT-7. for example, antigenic peptides characteristic of tumour include those listed in Table A below.

Table A: Exemplary Antigens

Gene	MHC	Peptide	Position	SEQ ID NO:
MAGE-1	HLA-A1	EADPTGHSY	161-169	8
	HLA-Cw16	SAYGEPRKL	230-238	9
MAGE-1	HLA-A1	EVDPIGHLY	168-176	10
	HLA-A2	FLWGPRALV	271-279	11
	HLA-B44	MEVDPIGHLY	168-176	12
BAGE	HLA-Cw16	AARAVFLAL	2-10	13
GAGE-1,2	HLA-Cw16	YRPRPRRY	9-16	14
RAGE	HLA-B7	SPSSNRIRNT	11-20	15
GnT-V	HLA-A2	VLPDVFIRC(V)	2-10/11	16,17
MUM-1	HLA-B44	EEKLVVLF	exon 2/intron	18
		EEKLSVVLF (wild type)		19
CDK4	HLA-A2	ACDPHSGHFV	23-32	20
		ARDPHSGHFV (wild type)		21
β -catenin	HLA-A24	SYLDSGIHF	29-37	22
		SYLDSGIHS (wild type)		23
Tyrosinase	HLA-A2	MLLAVLYCL	1-9	24
	HLA-A2	YMNGTMSQV	369-377	25
	HLA-A2	YMDGTMSQV	369-377	41
	HLA-A24	AFLPWHRLF	206-214	26
	HLA-B44	SEIWRDIDF	192-200	27
	HLA-B44	YEIWRDIDF	192-200	28
	HLA-DR4	QNILLSNAPLGQFP	56-70	29
	HLA-DR4	DYSYLQDSDPDSFQD	448-462	30

MELAN-A MART-1	HLA-A2	(E)AAGIGILTV	26/27-35	31,32
	HLA-A2	ILTVILGVL	32-40	33
gp100 ^{Pmel 117}	HLA-A2	KTWGQYWQV	154-162	34
	HLA-A2	ITDQVPPSV	209-217	35
	HLA-A2	YLEPGPVTA	280-288	36
	HLA-A2	LLDGTATLRL	457-466	37
	HLA-A2	VLYRYGSFSV	476-485	38
DAGE (PRAME)	HLA-A24	LYVDSLFFL	301-309	39
MAGE-6	HLA-Cw16	KISGGPRISYPL	292-303	40

Other examples will be known to one of ordinary skill in the art (for example, see
 5 Coulie, Stem Cells 13:393-403, 1995) and can be used in the invention in a like manner as those disclosed herein. One of ordinary skill in the art can prepare polypeptides comprising one or more *MAGE-A10* peptides and one or more of the foregoing tumour rejection peptides, or nucleic acids encoding such polypeptides, according to standard procedures of molecular biology.

10

Thus polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g. concatenated, overlapping). The polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, 15 to test the effectiveness of the polytope in stimulating, enhancing and/or provoking an immune response.

20

The polypeptides can be joined together to directly or via the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art (see e.g., Thomson et al. Proc. Acad. Sci USA 92(13):5485-5849), 1995;

Gilbert et al, Nature Biotechnol. 15(12):1280:1284, 1997; Thomson et al., J. Immunol. 157(2):822:826, 1996; Tam et al., J. Exp. Med. 171(1):299-306, 1990). For example, Tam showed that polytopes consisting of both MHC class I and class II binding epitopes successfully generated antibody and protective immunity in a mouse model. Tam also demonstrated that polytopes comprising "strings" of epitopes are processed to yield individual epitopes which are presented by MHC molecules and recognised by CTLs. Thus polytopes containing various numbers and combinations of epitopes can be prepared and tested for recognition by CTLs and for efficacy in increasing an immune response.

10 It is known that tumours express a set of tumour antigens, of which only certain subsets may be expressed in the tumour of any given patient. Polytopes can be prepared which correspond to the different combination of epitopes representing the subset of tumour rejection antigens expressed in a particular patient. Polytopes
15 can be prepared to reflect a broader spectrum of tumour rejection antigens known to be expressed by a tumour type. Polytopes can be introduced to a patient in need of such treatment as polypeptide structures, or via the use of nucleic acid delivery systems known in the art (see, e.g., Allsop et al., Eur. J. Immunol. 26(8):1951-1959, 1996). Adenovirus, pox virus, Ty-virus like particles, adeno-associated virus,
20 plasmids, bacteria, etc. can be used in such a delivery. One can test the polytope delivery systems in mouse models to determine efficacy of the delivery system. The systems can also be tested in human clinical trials.

As part of the immunisation protocols, substances which potentiate the immune
25 response may be administered with the nucleic acid or peptide components of a pharmaceutical composition or a cancer vaccine in accordance with the invention. Such immune response potentiating compound may be classified as either adjuvants or cytokines. Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages
30 and stimulating specific sets of lymphocytes. Adjuvants of many kinds are well known in the art; specific examples include MPL (SmithKline Beecham), a congener obtained after purification and acid hydrolysis of *Salmonella mimesota* Re 595 lipopolysaccharide. QS21 (SmithKline Beecham), a pure QA-21 saponin purified

from *Quillja saponaria* extract, and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol. Cytokines are also useful in vaccination protocols as a result of lymphocyte stimulatory properties. Many cytokines useful for such purposes will be known to one of ordinary skill in the art, 5 including interleukin-12 (IL-12) which have been shown to enhance the protective effects of vaccines (Science 268:1432-1434, 1995), GM-CSF and IL-18. As envisaged herein, cytokines can be produced *in vivo* by cells transformed or transfected to express nucleic acid molecules coding therefor.

10 There are a number of additional immune response potentiating compounds that can be used in vaccination protocols. These include co-stimulatory molecules provided in either protein or nucleic acid form. Such co-stimulatory molecules include the B7-1 and B7-2 (CD80 and CD86 respectively) molecules which are expressed on dendritic cells (DC) and interact with the CD28 molecule expressed on 15 the T cell. This interaction provides costimulation (signal 2) to an antigen/MHC/TCR stimulated (signal 1) T cell, increasing cell proliferation and effector function. B7 also interacts with CTLA4 (CD152) on T cells and studies involving CTLA4 and B7 ligands indicate that the B7-CTLA4 interaction can enhance antitumour immunity and CTL proliferation (Zheng et al., Proc. Nat'l Acad. Sci. USA 95:6284-6289, 1998).

B7 typically is not expressed on tumour cells so they are not efficient antigen presenting cells (APCs) for T cells. Induction of B7 expression would enable the tumour cells to stimulate more efficiently CTL proliferation and effector function. 25 A combination of B7/IL-6/IL-12 costimulation has been shown to induce IFN-gamma and a Th1 cytokine profile in the T cell population leading to further enhanced T cell activity (Gajewski et al., J. Immunol. 154:5637-5648, 1995). Tumour cell transfection with B7 has been discussed in relation to *in vitro* CTL expansion for adoptive transfer immunotherapy by Wang et al., (J. Immunol. 19:1-8, 30 1986). Other delivery mechanisms for the B7 molecule would include nucleic acid (naked DNA) immunization (Kim et al., Nature Biotechnol. 15:7:641-646, 1997) and recombinant viruses such as adeno and pox (Wendtner et al., Gene Ther. 4:726-735, 1997). These systems are all amenable to the construction and use of expression

cassettes for the coexpression of B7 with other molecules of choice, such as polypeptides or proteins in accordance with the invention (including polytopes), or cytokines. These delivery systems can be used for induction of the appropriate molecules in vitro vaccination situations. The use of anti-CD28 antibodies to directly stimulate T cells in vitro and in vivo could also be considered.

Lymphocyte function associated antigen-3 (LFA-3) is expressed on APCs and some tumour cells and interacts with CD2 expressed on T cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 co-stimulatory interaction (Parra et al., J. Immunol., 158:637-642, 1997; Fenton et al., J. Immunother. 21:95-108, 1998).

Lymphocyte function associated antigen-1 (LFA-1) is expressed on leukocytes and interacts with ICAM-1 expressed on APCs and some tumour cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 co-stimulatory interaction (Fenton et al., 1998). LFA-1 is thus a further example of a co-stimulatory molecule that could be provided in a vaccination protocol in the various ways discussed above for B7.

Complete CTL activation and effector function requires Th cell help through the interaction between the Th cell CD40L (CD40 ligand) molecule and the CD40 molecule expressed by DCs (Ridge et al., Nature 393:474, 1998; Bennett et al., Nature 393:478, 1998; Schoenberger et al., Nature 393:480, 1998). This mechanism of this co-stimulatory signal is likely to involve upregulation of B7 and associated IL-6/IL-12 production by the DC (APC). The CD40-CD40L interaction thus complements the signal 1 (antigen/MHC-TCR) and signal 2 (B7-CD28) interactions.

The use of anti-CD40 antibodies to stimulate DC cells directly, would be expected to enhance a response to tumour associated antigens which are normally encountered outside of an inflammatory context or are presented by non-professional APCs (tumour cells). In these situations Th help and B7 costimulation signals are not provided. This mechanism might be used in the context of antigen

pulsed DC based therapies or in situations where Th epitopes have not been defined within known tumour associated antigen precursors.

Pharmaceutical compositions in accordance with the present invention can be formulated with conventional pharmaceutically acceptable carriers and excipients, either for systemic or local administration. Such carriers and excipients can be selected without difficulty by those skilled in the art and include those which provide for immediate and sustained release.

The present invention involves the generation of *MAGE*-specific CTLs from a patient other than MZ2 by MLTC for the first time. A CTL clone (CTL 477A/5) was generated that recognises the nonapeptide (TRA) GLYDGMEHL (SEQ. ID. NO. 42) encoded by *MAGE-A10* in the context of HLA-A2. Its overlapping decapeptide (TRA) GLYDGMEHLI (SEQ. ID. NO. 44) could also sensitise target cells to be lysed by the CTL, but less efficiently. CTL 447A/5 recognised not only autologous tumour cells but *MAGE-A10+* tumour cells from other HLA-A2 patients (Fig. 6), suggesting that GLYDGMEHL (SEQ. ID. NO. 42) is a common TRA presented in tumours expressing *MAGE-A10* and HLA-A2. *MAGE-A10* is expressed in tumours more frequently than previously anticipated. By reverse-transcription-PCR, the expression of *MAGE-A10* gene has been detected in a variety of tumours, including melanomas, lung cancers, head and neck carcinomas, bladder carcinomas, myelomas, prostatic carcinomas, and (see table 2 below). As observed for other *MAGE* genes, the only normal tissue expressing *MAGE-A10* is testis.

Clinical trials have also been under way to treat melanoma patients with peptides derived from *MAGE-A1* and *MAGE-A3*. A few patients showed objective tumour regressions after being immunised with pure peptides, though peptide-specific CTL responses were not detected (Marchand, M., et al., 1995, *Int. J. Cancer.* 63:883- 885). When immunised with peptide-pulsed antigen presenting cells or dendritic cells, quite a few patients developed peptide-specific delayed-type hypersensitivity or CTL responses (Nestle, F.O., et al., 1998, *Nat. Med.* 4:328-332; Mukherji, B., Net al., 1995, *Proc. Natl. Acad. Sci. USA.* 92:8078-8082; and Hu, X., et al., 1996, *Cancer Res.*

56:2479-2483). One of the obstacles in cancer immunotherapy is the occurrence of antigen loss tumour variants. Since most tumours expressing *MAGE-A10* also express *MAGE-A1* or/and *MAGE-A3* (F. Brasseur, unpublished data), it is anticipated that addition of peptides in accordance with the present invention in a 5 cocktail vaccination will improve the anti-tumour effect by targeting several different antigens.

The following examples show the generation of cytolytic T lymphocytes (CTLs) from patent LB 1751, using MLTC techniques, that lysed specifically autologous 10 tumour cells and produced tumour necrosis factor (TNF) upon stimulation with target cells expressing *MAGE-A10*. The recognition by the CTLs was shown to be restricted by HLA-A2.1 and the antigen was found to be encoded by *MAGE-A10* in the region of nt 547-825. From the amino acid sequence corresponding to this 15 region, four peptides were found that had the potential to bind to HLA-A2.1. The expression of *MAGE-A10* has been detected in a variety of tumours, but not in normal tissues except testis and the identified antigenic peptides, therefore, clearly add to the repertoire of antigens that have the potential to be used in anti-tumoural vaccination trials.

20 **Brief description of the Sequences**

SEQ. ID. NO. 1 is the amino acid sequence of the protein encoded by the *MAGE-A10* gene;

SEQ. ID. NO. 2 is the amino acid sequence of the protein encoded for by the *MAGE-A8* gene;

25 SEQ. ID. NO. 3 is the nucleotide sequence of the *MAGE-A10* gene;

SEQ. ID. NO. 4 is the nucleic acid sequence of *MAGE-A10* cDNA, the region coding for the amino acid sequence in SEQ. ID. NO. 1 lies between bases 357 and 1466;

SEQ. ID. NO. 5 is the nucleotide sequence of the *MAGE-A8* gene;

30 SEQ. ID. No. 6 is a partial sequence of the *MAGE-A8* gene as published in WO92/20356, with the codons in the coding portion of the gene identified; and

SEQ. ID. NO. 7 is a partial sequence of the *MAGE-A10* gene as published in WO92/20356, with the codons in the coding portion of the sequence identified;

SEQ. ID. NOs. 8-41 are described in Table A;

SEQ. ID. NO. 42 is the nonapeptide with the amino acid sequence GLYDGMEHL;

SEQ. ID. NO. 43 is the nonapeptide with the amino acid sequence GLYDGREHS;

SEQ. ID. NO. 44 is the decapeptide with the amino acid sequence GLYDGMEHLI;

5 SEQ. ID. NO. 45 is the decapeptide with the amino acid sequence

GLYDGREHSV;

SEQ. ID. NO. 46 is the nonapeptide with the amino acid sequence MLLVFGIDV;

SEQ. ID. NO. 47 is the decapeptide with the amino acid sequence CMLLVFGIDV;

SEQ. ID. NO. 48 is the nonapeptide with the amino acid sequence FLLFKYQMK;

10 SEQ. ID. NO. 49 is the nonapeptide with the amino acid sequence FIEGYCTPE;

SEQ. ID. NO. 50 is the nonapeptide with the amino acid sequence GLELAQAPL;

SEQ. ID. NO. 51 is the sense primer referred to in Example 3;

SEQ. ID. NO. 52 is the first anti-sense primer referred to in Example 3;

SEQ. ID. NO. 53 is the second anti-sense primer referred to in Example 3;

15 SEQ. ID. NO. 54 is the third anti-sense primer referred to in Example 3;

SEQ. ID. NO. 55 is the sense primer referred to in Example 6; and

SEQ. ID. NO. 56 is the anti-sense primer referred to in Example 6.

Brief description of the Figures

20 **Figure 1.** Shows the specific lysis of autologous LB 1751-MEL cells by CTL 447A/5. Control targets included autologous EBV-transformed lymphoblastoid line LB1751-EBV and NK-sensitive line K562. Chromium release was measured after 4 h of incubation of chromium labelled target cells with the CTL at different effector to target ratios.

25 **Figure 2.** Shows the HLA-restricted recognition of LB1751-MEL cells by CTL 447A/5. LB1751-MEL cells alone or in the presence of mAbs with the specificities indicated were used to stimulate CTL 447A/5. After 24 h of coculture, production of TNF by the CTL was measured by testing toxicity of the supernatants to TNF-sensitive WEHI-164.13 cells.

30 **Figure 3.** Shows the identification of the region coding for the antigenic peptide recognised by CTL 447A/5. PCR fragments of different lengths as indicated were cloned into pcDNA1/Amp and cotransfected into COS-7 cells with gene HLA-

A2.1. Transfected cells were incubated for 24 h with CTL 447A/5 and the TNF in the supernatants was measured by its toxicity to WEHI-164.13 cells.

Figure 4. Shows the extent of lysis by CTL 447A/5 of peptide-sensitised LB1751-EBV cells. (A) LB1751-EBV cells pulsed with peptides derived from *MAGE-A10*.

5 Chromium-labelled autologous EBV-transformed lymphoblastoid cells LB1751-EBV were pulsed for 30 min with peptides as indicated at various concentrations before addition of CTL 447A/5 at an E/T ratio of 20. Chromium release was measured after 4 h. (B) Enhancement by mAb MA2.1 of lysis of LB 1751-EBV cells pulsed with *MAGE-A10* peptides. LB1751-EBV cells were pre-treated with or 10 without anti-HLA-A2 antibody MA2.1. The pre-treatment was performed by adding mAb MA2.1 during ⁵¹Cr-labeling. Peptide sensitisation and chromium release assay were carried out as in (A).

15 **Figure 5.** Shows the extent of lysis by CTL 447A/5 of LB1751-EBV cells sensitised with peptides derived from *MAGE-A8*. LB1751-EBV cells were pre-treated with or without anti-HLA-A2 antibody MA2.1. Ab treatment and peptide sensitisation of the cells and chromium release assay were carried out as in Fig. 4.

20 **Figure 6.** Shows the degree of recognition of allogenic tumour cell lines by CTL 447A/5. LB373-MEL (*MAGE-A10+*), AVL3-MEL (*MAGE-A10+*) and TT (*MAGE-A8+*) cell lines derived from HLA-A2 patients were used to stimulate CTL 447A/5. Autologous tumour cell line LB1751-MEL was included as a control. After 24 h of coculture, production of TNF by the CTL was measured by testing toxicity of the supernatants to TNF-sensitive WEHI-164.13 cells.

25 **Figure 7.** Shows the amino acid sequence of the protein encoded by the *MAGE-A10* gene (SEQ. ID. NO. 1).

30 **Figure 8.** Shows the amino acid sequence of the protein encoded for by the *MAGE-A8* gene (SEQ. ID. NO. 2).

Figure 9. Shows the nucleotide sequence of the *MAGE-A10* gene (SEQ. ID. NO. 3).

35 **Figures 10a and 10b.** Show the nucleic acid sequence of *MAGE-A10* cDNA, the region coding for the amino acid sequence in SEQ. ID. NO. 1 lying between bases 357 and 1466 (SEQ. ID. NO. 4).

Figures 11a and 11b. Show the nucleotide sequence of the *MAGE-A8* gene (SEQ. ID. NO. 5).

Figure 12. Shows a partial sequence of the *MAGE-A8* gene as published in WO92/20356, with the codons in the coding portion of the gene identified (SEQ. ID. NO. 6).

Figure 13. Shows a partial sequence of the *MAGE-A10* gene as published in WO92/20356, with the codons in the coding portion of the sequence identified (SEQ. ID. NO. 7).

Example 1

Preparation of CTL Clones against LB1751-MEL and identification HLA-A2.1 as on the presenting MHC molecule.

Melanoma cell line LB1751-MEL was derived from a metastatic melanoma in axillary lymph nodes of a 67-yr-old male patient LB1751 and grown by a method previously described (Van den Eynde, B., et al., 1989, *Int. J. Cancer.* 44:634-640).

At passage 4 after the initiation of LB1751-MEL culture, aggregates of typical EBV-transformed lymphoblastoid cells appeared in the supernatant. They were collected and cultured separately to obtain B cell line LB 1751-EBV. Melanoma culture LB1751-MEL was cleared of EBV-transformed B cells by limiting dilution cloning. DNA fingerprint confirmed that LB 1751-MEL and LB 1751-EBV originated from the same patient (data not shown). A panel of CTL clones was generated by MLTC as described previously with minor modifications (Herin, M., et al., 1987, *Int. J. Cancer.* 39:390-396). Briefly, MLTC was carried out by culturing PBL of patient LB1751 with irradiated LB1751-MEL cells in an 8% CO₂ incubator in Iscove's modified Dulbecco's medium (GIBCO BRL, Gaithersburg, MD) supplemented with 10 mM Hepes buffer, L-arginine (116µg/ml), L-asparagine (36µg/ml), L-glutamine (216g/ml), 10% human serum, and 5 ng/ml of recombinant human IL-7 (rhIL-7) (Genzyme, Cambridge, MA). On day 3, rhIL-2 (Eurocetus, Amsterdam, Netherlands) was added at a final concentration of 25 U/ml. Lymphocytes were restimulated weekly with irradiated LB1751-MEL cells in fresh medium containing 25U/ml of rhIL-2 and 5 ngl/ml of rhIL-7. On day 21, CD8+ T lymphocytes were sorted by using anti-CD8-conjugated MACS magnetic MicroBeads (MACS, Miltenyi Biotec GmbH, Germany) and cloned by limiting dilution. The resulting panel of CTL clones specifically lysed LB1751-MEL cells, but not autologous EBV-

transformed B cell line LB 1751-EBV or NK-sensitive cell line K562. Lysis of target cells was tested by chromium release as previously described in (Boon, T., et al., 1980, *J. Exp. Med.* 152:1184-1193) and the results of these tests for representative CTL clone 447A/5 are shown in Fig. 1.

5

The ability of CTL clone 447A/5 to produce TNF when stimulated with LB1751-MEL cells was confirmed using the technique described in (Traversari, C., et al., 1992, *Immunogenetics*. 35:145-152). Briefly, 2×10^4 tumour cells were grown for 24 h. The medium was discarded and 3,000 CTL were added to the microwells in 100 μ l 10 of Iscove's modified Dulbecco's medium supplemented with 10% human serum and 25 U/ml rhIL-2. After 24 h, the supernatant was collected and its TNF content was determined by testing its cytotoxic effect on WEHI 164 clone 13 cells (Espevik, T., et al., 1986, *J. Immunol. Methods*. 95:99-105) in a MTT colorimetric assay (Traversari, C., et al., 1992, *Immunogenetics*. 35:145-152; and Hansen, M. B., et al., 1989, *J. Immunol. Methods*. 119:203-210). Inhibition of TNF production by mAbs W6/32 15 (anti-HLA class I) (Bamstable, C.J., et al., 1978, *Cell*. 14:9-20), BB7.2 (anti-HLA-A2) (Parham, P., and F.M. Brodsky, 1981, *Hum. Immunol.* 3:277-299), and B1.23.2 (anti-HLA-B and -C) (Rebai, N., and B. Malissen, 1983, *Tissue Antigens*. 22:107-117) 20 was tested by adding a 1/20 dilution of ascites to the test, and it was found that production of TNF was inhibited by mAbs W6/32 (anti-HLA class I) and BB7.2 (anti-HLA-A2), but not by mAb B1.23.2 (anti-HLA-B, -C) (Fig. 2), indicating that the target antigen is presented by HLA-A2. The results of the test are set out in 25 Figure 2.

25

Example 2

Identification of the genes encoding the antigen recognised by CTL 447A/5

30

Because of the high level expression of almost all the *MAGE-A* genes in melanoma cell line LB1751-MEL (data not shown), the possibility that CTL 447A/5 recognises an antigen encoded by one of the *MAGE-A* genes was tested. COS-7 cells were cotransfected with the cDNA of *MAGE-A* genes cloned in expression vector pcDNAI/Amp together with pcDNAI/Amp-A2, a construct encoding the HLA-A2.1. Transfection was performed by the DEAE-dextran-chloroquine method

(Seed, B., et al., 1987, *Proc. Natl. Acad. Sci. USA.* 84:3365-3369). Briefly, 2×10^4 COS-7 cells were transfected with 100 ng of plasmid pcDNAI/Amp-A2, a recombinant plasmid containing the HLA-A2.1 gene isolated from a CTL clone of patient SK29 (Wolfel, T., et al., 1993, *Int. J. Cancer.* 55:237-244), and 100 ng of DNA of *MAGE-A* genes cloned in pcDNAI/Amp. The transfectants were grown for 48 hours and then tested for their ability to stimulate TNF production by CTL 447A/5 by the method described in Example 1. The tests revealed that a very significant amount of TNF was produced by CTL 447A/5 when stimulated with COS-7 cells transfected with *MAGE-A10 DNA*. Transfectants with *MAGE-A8 cDNA* could also stimulate CTL 447A/5 to produce TNF, but less efficiently than those with *MAGE-A10 cDNA*. No stimulation was observed with COS-7 cells transfected with HLA-A2.1 alone or with the combination of HLA-A2.1 and any of the other *MAGE-A* genes. The results of these tests are set out in table 1.

15

Table 1. Stimulation of CTL 447A/5 by COS-7 cells transfected with HLA-A2.1 and MAGE-A genes

Stimulator cells	TNF released by CTL 447A/5 (pg/ml)
LB1751-MEL	28
COS	7
COS+HLA-A2.1	4
COS+HLA-A2.1 +	
MAGE-A1	3
MAGE-A2	4
MAGE-A3	4
MAGE-A4	4
MAGE-A6	4
MAGE-A8	30
MAGE-A9	3
MAGE-A10	>120
MAGE-A11	4
MAGE-A12	2

Control stimulator cells included autologous LB1751-MEL, untransfected COS-7 cells, and COS-7 cells transfected only with HLA-A2.1 gene.

Example 3*Identification of the MAGE-A10 Antigenic Peptides.*

Fragments of different lengths starting from the initiation codon of *MAGE-10* (nucleotide 1955 in SEQ. ID. NO. 3) were generated by PCR amplification.

The 1.1-kb open reading frame (ORF) of *MAGE-A10* was cloned in plasmid vector pcDNAI/Amp (Invitrogen Corporation, Oxon, UK). Three fragments containing the first 270, 546 and 825 nucleotides of the *MAGE-A10* open reading frame (ORF) (nucleotides 1955-3064 in SEQ. ID. No. 3) were amplified by PCR using sense

primer 5'-GGAATTCCATCATGCCTCGAGCTCAAAGC-3' (SEQ. ID. NO. 51) and three anti-sense primers 5'-GCTCTAGAGCTTAGGCTATCTGAGCACTCTG-3' (SEQ. ID. NO. 52), 5'-GCTCTAGAGCTTACACTCGGAGGCTTCAC-3' (SEQ. ID. NO. 53), and 5'-GCTCTAGAGCTTACCAATCTGGGTGAGCAG-3' (SEQ. ID. NO. 54) respectively. For PCR amplification *Pfu* DNA polymerase (STRATAGENE, La Jolla, CA) was used. A first denaturation step was done for 5 min at 94°C. The first cycle of amplification was performed for 1 min at 94°C followed by 1 min at 53°C and 1 min at 72°C, and then additional 25 cycles were performed as follows: 1 min at 94°C, 1 min at 65°C, and 1 min at 72°C. Cycling was concluded with a final extension step of 15 min at 72°C.

The PCR products were digested with EcoRI and Xba I, unidirectionally cloned into the EcoRI and Xba I sites of plasmid pcDNAI/Amp and transfected into COS-7 cells together with pcDNAI/Amp-A2, using the DEAE-dextran-chloroquine method described in Example 2. A CTL stimulation assay was carried out with the transfectants in the manner described in Examples 1 and 2. As shown in Fig. 3, the fragment of 825 bp rendered the transfectants capable of stimulating TNF production by CTL 447A/5, and the 546 bp fragment did not, indicating that the sequence coding for the antigenic peptide is located between nt 547 and 825 of the *MAGE-A10* ORF.

In the amino acid sequence corresponding to the nucleotides 547-825 there are two nonapeptides, MLLVFGIDV (codons 183-191 in the ORF) (SEQ. ID. NO. 46) and GLYDGMEHL (254-262) (SEQ. ID. NO. 42), which conform to the HLA-A2.1

peptide binding motif, i.e., a nona- or decapeptide with Leu or Met at position 2 and Leu, Val or Ile at its C-terminus (Rammensee, H.G., et al., 1995, *Immunogenetics*. 41:178-228). These two peptides and their overlapping decapeptides were synthesised on solid phase using F-moc for transient NH₂-terminal protection and characterised by mass spectrometry. The peptides were >90% pure, as indicated by analytical HPLC, and used to sensitise autologous lymphoblastoid cell line LB1751-EBV in a chromium release assay as described in (Boon, T., et al., 1980, *J. Exp. Med.* 152:1184-1193) but modified as follows. The target cells were ⁵¹Cr-labeled for 1 h at 37°C and then washed extensively. 1,000 target cells were then incubated in 10 96-well microplates in the presence of various concentrations of peptides for 30 min at 37°C and CTLs were added at an E/T ratio of 20. Chromium release was measured after 4 h at 37°C.

It was found that the nonapeptide GLYDGMEHL (254-262) (SEQ. ID. NO. 42) and, less efficiently, the decapeptide GLYDGMEHLI (254-263) (SEQ. ID. NO. 44), could sensitise LB1751-EBV cells to lysis by CTL 447A/5 (Fig. 4A). When pre-treated with anti-HLA-A2 antibody MA2.1 for 1 h before peptide sensitisation, LB1751-EBV cells pulsed with both peptides showed a significantly increased sensitivity to lysis by the CTL (Fig. 4B). mAb MA2.1 can facilitate the binding of peptides to HLA-A2 molecules on the cell surface, thereby augmenting lysis of peptide-sensitised target cells by HLA-A2-restricted peptide-specific CTL (Bodmer, H., et al., 1989, *Nature* 342:443-446). Enhancement of peptide binding to the HLA-A2 molecule was achieved by incubation of target cells during ⁵¹Cr-labeling with a 1/5 dilution of hybridoma culture supernatant of mAb MA2.1 (McMichael, A.J., et al., 1980, *Hum. Immunol.* 1:121-129; and Bodmer, H., et al., 1989, *Nature* 342:443-446). The other two peptides MLLVFGIDV (183-191) (SEQ. ID. NO. 46) and CMLLVFGIDV (182-191) (SEQ. ID. NO. 47) failed to confer recognition by the CTLs, even after LB1751-EBV cells were treated with mAb MA2. 1.

30 **Example 4**

Identification of MAGE-A8 antigen peptides

The sequence of *MAGE-A8*, which is homologous to that of the *MAGE-A10* gene

encoding GLYDGMEHL (SEQ. ID. NO. 42), codes for peptide GLYDGREHS (codons 232-240 in the *MAGE-A8* ORF) (SEQ. ID. NO. 43) that displays two amino acid changes at positions 6 and 9. This peptide and its overlapping decapeptide GLYDGREHSV (codons 232-241) (SEQ. ID. NO. 45) were synthesised by the technique described above. LB1751-EVB cells incubated with either of the peptides, at a concentration of as high as 10 µM peptide, were not lysed by CTL 447A/5. However, when the peptide concentration was increased to 100 µM could GLYDGREHS (SEQ. ID. NO. 43) did sensitise LB1751-EBV cells to lysis (Fig. 5). An enhancement of lysis was observed when the LB1751-EBV cells were pre-treated with mAb MA2.1 and pulsed with GLYDGREHS (SEQ. ID. NO. 43), but not GLYDGREHSV (SEQ. ID. NO. 45). Enhancement of peptide binding to the HLA-A2 molecule was achieved by incubation of target cells during ⁵¹Cr-labeling with a 1/5 dilution of hybridoma culture supernatant of mAb MA2.1 (McMichael, A.J., et al., 1980, *Hum. Immunol.* 1: 121-129; and Bodmer, H., et al., 1989, *Nature* 342:443-446).

Example 5

MAGE-A10+ Allo-tumours Present the Antigen Recognised by CTL 447A15.

Using allogenic HLA-A2+ tumour cell lines that express *MAGE-A10* or *MAGEA8* as stimulator cells, a CTL stimulation assay of the type described above was performed to assess the TNF production by CTL 447A/5. Melanoma cell lines LB373-MEL and AVL3-MEL were derived from patients LB373 and AVL, respectively, and cultured in Iscove's modified Dulbecco's medium containing 10% FCS. Medullary thyroid carcinoma cell line TT (ATCC® No.: CRL1803) was obtained from the American Type Culture Collection (Rockville, MD) and maintained in DMEM supplemented with 10% FCS. The results of these assays are set out in Fig. 6 and show that two *MAGE-A10+* cell lines LB373-MEL and AVL3-MEL could stimulate CTL 447A/5 to produce TNF, but *MAGE-A8+* cell line TT could not. Moreover, AVL3-MEL cells were recognised by CTL 447A/5 less efficiently than LB373-MEL cells, which is consistent with the finding that the transcription level of *MAGE-A10* in AVL3-MEL was lower than that in LB373-MEL (Serrano, et. al. manuscript in preparation).

Example 6

MAGE-A10 is Expressed in a Variety of Tumours.

As the expression of *MAGE-A10* has been studied only in a small number of tumours, a series of 314 tumours of various histological types were tested by RT-PCR with primers ensuring specificity for gene *MAGE-A10*. Briefly, reverse-transcription-PCR (RT-PCR) was performed to detect the expression of *MAGE-A10* in tumour tissues. Total RNA purification and cDNA synthesis were carried out as previously described (Weynants et al. Int. J. Cancer. 56:826-829, 1994).
1/40th of the cDNA produced from 2µg of total RNA was amplified using sense primer 5'-CACAGAGCAGCACTGAAGGAG-3' (SEQ. ID. NO. 55) and anti-sense primer 5'-CTGGGTAAAGACTCACTGTCTGG-3' (SEQ. ID. NO. 56), which yielded a 485-bp specific fragment of *MAGE-A10*. For PCR, a first denaturation step was done for 4 min at 94° and then 30 cycles of amplification were performed as follows: 1 min at 94°C, 1 min at 65°C, and 1 min at 72°C. Cycling was concluded with a final extension step of 15 min at 72°C. As shown in Table 2, *MAGE-A10* was expressed in a number of tumours of various histological types. The expression of some other *MAGE* genes was also examined by RT-PCR. Of the 71 tumour samples expressing *MAGE-A10*, all but two expressed simultaneously at least one of genes *MAGE-A1, A2, A3, A4* and *A6* (data not shown).

Table 2. Expression of MAGE-A10 in Tumors

Tumor type	Positive samples/ samples tested*
Bladder carcinomas	
Superficial	5/15 (33%)
Infiltrating	5/15 (33%)
Brain tumors	0/9
Breast carcinomas	0/20
Colorectal carcinomas	0/20
Esophageal squamous carcinomas	6/15 (40%)
Head and neck squamous carcinomas	7/20 (35%)
Leukemias	0/25
Lung carcinomas	
Adenocarcinomas	6/15 (40%)
Squamous carcinomas	10/20 (50%)
Melanomas (of cutaneous origin)	
Primary lesions	4/19 (21%)
Metastases	21/45 (47%)
Mesotheliomas	0/4
Myelomas	3/15 (20%)
Neuroblastomas	2/2
Prostatic carcinomas	1/10 (10%)
Renal carcinomas	0/20
Sarcomas	1/15 (7%)
Thyroid carcinomas	0/5
Uterine carcinomas	0/5

* Expression of *MAGE-A10* was tested by RT-PCR on total RNA with specific primers which give a 485-bp product when cDNA is amplified. Percentage of positive samples is shown in parentheses.

Claims

1. An isolated polypeptide comprising an unbroken sequence of amino acids from SEQ ID. NO. 1, or 2, characterised by an ability to complex with a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.
2. An isolated polypeptide comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2, characterised by an ability to elicit an immune response from human lymphocytes.
3. A nonapeptide comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2, wherein the amino acid adjacent to the N-terminal amino acid is L or M, preferably L, and the C-terminal amino acid is L, V, or I, preferably L.
4. A nonapeptide as claimed in claim 3, wherein the amino acid in position 3 is Y and/or the amino acid in position 4 is D and/or the amino acid in position 5 is G and/or the amino acid in position 7 is E and/or the amino acid in position 8 is H.
5. A polypeptide as claimed in any one of claims 1-4, other than a nonapeptide having any one of amino acid sequences:-
 - (a) FLLFKYQMK;
 - (b) FIEGYCTPE; or
 - (c) GLEGAQAPL.
6. A polypeptide as claimed in any one of claims 2-5, further characterised by an ability to complex with a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.
7. A decapeptide comprising a nonapeptide as claimed in any of claims 3-5 and, preferably, an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2.
8. A nonapeptide having the amino acid sequence GLYDGMEHL or GLYDGREHS, preferably GLYDGMEHL.

9. A decapeptide having the amino acid sequence GLYDGMEHLI or GLYDGREHSV, preferably GLYDGMEHLI.
- 5 10. An isolated polypeptide of up to about 93 amino acids in length, characterised by comprising a nonapeptide or a decapeptide as claimed in any of claims 3-9.
- 10 11. A polypeptide as claimed in claim 10 comprising of an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2.
12. A polypeptide as claimed in any of the preceding claims, wherein the unbroken sequence is from SEQ. ID. NO. 1.
- 15 13. A polypeptide as claimed in any of the preceding claims and capable of eliciting an immune response from human lymphocytes.
- 20 14. A polypeptide as claimed in claim 13 and capable of eliciting an immune response from human lymphocytes when complexed with a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.
15. A polypeptide as claimed in claim 13 or claim 14, wherein said immune response is an cytolytic response from human T-lymphocytes.
- 25 16. An isolated polypeptide or protein comprising a polypeptide as claimed in any of claims 1-15, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in either of SEQ. ID. NOS. 1 and 2 or that coded for by nucleotides 334-918 of SEQ. ID. NO. 7.
- 30 17. An isolated polypeptide or protein which is a functionally equivalent homologue to a polypeptide or protein as claimed in any of claims 1-16, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in

either of SEQ. ID. NOS. 1 and 2 or that coded for by nucleotides 334-918 of SEQ. ID. NO. 7.

18. An isolated nucleic acid molecule comprising a nucleotide sequence coding for a polypeptide or protein as claimed in any of claims 1-16, or a complimentary nucleotide sequence, wherein said nucleotide sequence is not that set out in any of SEQ. ID. NOS. 3, 4, 5, 6 or 7.

19. A nucleic acid molecule as claimed in claim 18 and comprising an unbroken sequence of nucleotides from SEQ. ID. NO. 3, 4 or 5, or a complimentary sequence, or an RNA transcript of said nucleic acid molecule.

20. A nucleic acid molecule as claimed in claim 18 or claim 19, wherein said nucleotide sequence encodes a plurality of epitopes or a polytope.

15 21. An expression vector comprising a nucleic acid molecule as claimed in any of claims 18-20 operably linked to a promoter.

20 22. An expression vector as claimed in claim 21, further comprising a nucleotide sequence coding for a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1, a cytokine or a co-stimulatory molecule, or a bacterial or viral genome or a portion thereof.

25 23. A host cell transformed or transfected with an expression vector as claimed in claim 21 or claim 22.

24. A host cell as claimed in claim 23, transformed or transfected with an expression vector coding for a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1, a cytokine or a co-stimulatory molecule.

30 25. A polypeptide-binding agent which selectively binds or is specific for an isolated polypeptide or protein as claimed in any of claims 1-17.

26. A polypeptide-binding agent as claimed in claim 25, comprising an antibody, preferably a monoclonal antibody or an antibody fragment specific for an isolated polypeptide as claimed in any of claims 1-17.
- 5 27. A polypeptide-binding agent as claimed in claim 25 or claim 26 which selectively binds or is specific for a complex of a polypeptide as claimed in any of claims 1-17 and a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1, but which does not bind said major histocompatibility molecule alone.
- 10 28. A polypeptide-binding agent as claimed in any of claims 25-27, comprising a cytolytic T-cell which is specific for a complex of a polypeptide as claimed in any of claims 1-17 and a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.
- 15 29. A polypeptide or protein as claimed in any of claims 1-17, an isolated nucleic acid molecule as claimed in any of claims 18-20, an expression vector as claimed in either of claims 21 or 22, a host cell as claimed in either of claims 23 or 24, or a polypeptide binding agent as claimed in any of claims 25-28, for use in the therapy, 20 prophylaxis or diagnosis of tumours.
- 25 30. A pharmaceutical composition for the prophylaxis, therapy or diagnosis of tumours comprising a polypeptide or protein as claimed in any of claims 1-17, a nucleic acid molecule as claimed in any of claims 18-20, an expression vector as claimed in either of claims 21 or 22, a host cell as claimed in either of claims 23 or 24, or a polypeptide binding agent as claimed in any of claims 25-28, optionally in admixture with a pharmaceutically acceptable carrier and optionally further comprising a major histocompatibility molecule type HLA-A2, preferably HLA-A2.1.
- 30 31. A pharmaceutical composition for the prophylaxis, therapy or diagnosis of tumours comprising a polypeptide or protein as claimed in any of claims 1-17 complexed with a major histocompatibility molecule, HLA, and presented on the

surface of an APC, preferably a dendritic cell, wherein said complex is formed by pulsing said APC with polypeptide or protein.

32. A cell, preferably an APC, and more preferably, a dendritic cell, which has been pulsed with a polypeptide or protein as claimed in any of claims 1-17 to present on its surface said polypeptide or protein as a complex with a major histocompatibility molecule, HLA.

33. A pharmaceutical composition as claimed in any of claims 30 and 31 further comprising a co-stimulatory molecule.

34. A method of diagnosing disease, preferably cancer, comprising contacting a biological sample isolated from a subject with an agent that is specific for a polypeptide or protein as claimed in any of claims 1-17, or a nucleic acid molecule as claimed in any of claims 18-20, and assaying for interaction between the agent and any of the polypeptide, protein or nucleic acid molecule either free in or forming an integral part of the sample as a determination of the disease.

35. A method as claimed in claim 34, wherein the agent is a polypeptide-binding agent as claimed in any of claims 25-28.

36. A method of producing a cytolytic T-cell culture reactive against tumour cells, comprising removing a lymphocyte sample from an individual and culturing the lymphocyte sample with a polypeptide or protein as claimed in any of claims 1-14, an expression vector as claimed in either of claims 21 or 22, or a host cell as claimed in either of claims 23 or 24.

37. A product comprising cytolytic T-cells reactive against a tumour cell expressing an antigen comprising a polypeptide or protein as claimed in any of claims 1 to 17, for use in the prophylaxis, therapy or diagnosis of tumours.

38. A product as claimed in claim 37 and obtained or obtainable by a method as claimed in claim 36.

39. A method of treating tumours in a patient comprising administering a composition as claimed in any of claims 29, 30, 31, 33, 37 or 38 to the patient in an amount effective to control or prevent tumour growth.

1/16




Fig.1

2/16



Stimulator cells

Fig. 2

3/16

Sequence cotransfected with HLA-A2.1



TNF released by CTL 447A/5 (pg/ml)





Fig. 3


4/16

Fig. 4a



- CMLLVFGIDV(182 – 191)
- ▲ MLLVFGIDV(183 – 191)

Fig. 4b



- GLYDGMEHL(254 – 262)
- GLYDGMEHLI(254 – 263)

5/16




Fig. 5

- GLYDGREHS (No Ab)
- GLYDGREHS (MA2.1)
- ◇ GLYDGREHSV (No Ab)
- ◆ GLYDGREHSV (MA2.1)

6/16




Fig. 6

7/16

SEQ ID NO. 1

MPRAPKRQRCMPEEDLQSQSETQGLEGAQAPLAVEEDASSSTSTSSFPSSFPSSSSSSCYPLIPS
TPEEVASADDETNPQPSAQIACSSPSVVASLPLDQSDEGSSSQKEESPSTLQVLPDSESLPRSEIDEKV
TDLVQFLLFKYQMKEPITKAEILESVIKNYEDHFPLLSEASECMLLVFGIDVKEVDPTGHSFVLVTSL
GLTYDGMLSDVQSMPKTGILILILSIIIFIEGYCTPEEVIWEALNMMLYDGMEHLIYGEPRKLLTQDWV
QENYLEYRQVPGSDPARYEFLWGPRAHAEIRKMSLLKFLAKVNGSDPRSFPWLWYEALKDEEERAQDRI
ATTDDTTAMASASSSATGSFSYPE

Fig. 7

8/16

SEQ ID NO. 2

MLLGQKSQRYKAEGLQAQGEAPGLMDVQIPTAEEQKAASSSTLIMGTLEEVTDGSPPQSPEGAS
SSLTVTDSTLWSQSDEGSSSNEEGPSTSPDPAHLESLFREALDEKVAELVRFLLRKYQIKEPVTKAEM
LESVIKNYKNHFPDIIFSKASECMQVIFGIDVKEVDPAAGHSYILVTCLGLSYDGLLDDQSTPKTGLII
VLGMILMEGSRAPEEAIWEALSVMGAV

Fig. 8

9/16

Fig. 9

SEQ ID NO. 3

1 caggagatg gtggcttgg cgtgcacagac ccatacacga ttcagcagga gggaaaggct
 61 gggctgtcg gagaatctt gaataccctgg aggacacccca aataaaggaa gtccccgtct
 121 tgtccccctc ccctgcccac caccgggggg ccccccggcca aatgtctgct ctttctgtca
 181 gctttggaa tcccatgcag gtgtgatcgt gtgggtcccc tccccacttc tgcctgcccgg
 241 gtctcaggaa ggtgaggacc ttgggtctgag ggttgcataag aagttattac aggggttccac
 301 acttggtcaa cagagggagg agtcccagaa tctgcaggac ccaaggggtg cccccccttagt
 361 gaggacttgg a ggtacctgca gcccgaaaaa aaggatgtc acagagtctg gctgtccccct
 421 gttcttagct ctgagggac ctgatcagga ttggcactaa gtggcaagct caatttacc
 481 acaggcagga agatgaggaa ccctcaggaa aatggagtt tgggttaaag gggagatatc
 541 agccctggac accccacagg gatgacagga tgggtctct tcttactttt gttttggaaat
 601 ctcaggagg tgagaacctt gctctcagag ggtgactcaa gtcaacacag ggaacccctc
 661 ttttctacag acacagtggg tcgcaggatc tgacaagagt ccaggttaagg aacctgaggg
 721 aaatctgagg gtaccccccag cccataaacac agatggggtc cccacagaaa tctgccatga
 781 ccctactgtc actctggaga acccgatcag ggctgtccgc tgagtctccc tgccttatac
 841 aaggatcaact ggtctctggg agggagaggt gttggctaa gggagctgca ctcgggtcag
 901 cagagggagg gtcccagacc ctgccaggag tcaaggtag gactgagggg acaccattct
 961 ccaaacgcac aggactcagc cccacccctac cccttctgtc agccacggga attcatgggg
 1021 aactgggggt agatggactc ccctcacttc ctcttccat gtctcctgga ggtaggacct
 1081 tggtttaagg aagtggcctc agatcaacaa agggagggtc ccaggtcgta tcaggcatca
 1141 agaagaggac caagcaggct cctcaccctca gtacacatgg acccagctga atatggccac
 1201 ctcttgctgt ctttctggg aggacctctg cagttgtggc cagatgtggg tcccctcatg
 1261 tcttcttattt cgtatcaggg atgtaagctt ttgatctgag agtttcttag accagcaaag
 1321 gagcagggtc taggctttc caggagaaag gtgagagccc cacgtgagca cagaggctcc
 1381 ccaccccagg gtagtgggaa actcacagag tccagccac cctctgaca acactgggag
 1441 gctggggctg tgcttcagc ctgaaccctg agggccccc aattcctt tcaggagctc
 1501 cagggactgt gaggtgaggc ctgggtctaa ggcaatgttt tcaggtcaca gagcagaaag
 1561 ggcccgacca gtgccaggag tcaaggtag gtcgtcccc tgaatgtgta ccaagggccc
 1621 cacctgtcc accacaaagt ggacccact gcatcagctc caccctaccct actgtcagtc
 1681 ctggagcctt ggcctctgcc ggctgcattc tgaggagcca tctctcaact ctttcttcag
 1741 gttctcaggaa gacaggagaa gcaagaggtc aagagcttg ggacaccaca gagcagcact
 1801 gaaggagaag acctgttaagt tggctttgt tagaacctcc aggtgtggg tctcagctgt
 1861 ggccacttac accctccctc tctccccagg cctgtgggtc cccatcgccc aagtctgccc
 1921 cacactccca cctgttaccc tgatcagat catcatgcct cgagctccaa agcgtcagcg
 1981 ctgcattgcct gaagaagatc ttcaatccca aagtgagaca cagggctcg aggtgcaca
 2041 ggctccctg gctgtggagg aggtgttcc atcatccact tccaccagct cctctttcc
 2101 atcctctttt ccctcttccct cctcttccct ctcctctcc tgctatcctc taataccaag
 2161 caccctcaggag gaggttctg ctgatgtatc gacacaaat cctccccaga gtgctcagat
 2221 agcctgtcc tccccctcgg tggctgttc cttccatata gatcaatctg atgagggctc
 2281 cagcagccaa aaggaggaga gtccaagcac cctacaggc ctgccagaca gtgagtctt
 2341 acccagaagt gagatagatg aaaaggtgac tgatgggtc cagttctgc tcttcaagta
 2401 tcaaataatgaa gaggccatca caaaggcaga aataactggag agtgtcataaa aaaattatga
 2461 agaccacttc ctttggatgt ttgtgttgc cttcgagtgc atgctgtgg tcttggcat
 2521 tgatgttaaag gaagtggatc ccactggcca ctcccttgc tttgtcacct ccctgggcct
 2581 cacctatgtatc gggatgttca gtgtatgttca gagcatgccc aagactggca ttctcataact
 2641 tattcttaatc ataatctca tagagggata ctgcaccctt gaggaggta tctggaaagc
 2701 actgaatatg atggggctgt atgatggat ggacccatc attatgggg agcccaaggaa
 2761 gctgctcacc caagattggg tgcaggaaaa ctacctggag taccggcagg tgcctggcag
 2821 tgatcctgca cggtatgtat tttctgtggg tccaagggtc catgtgaaa ttaggaagat
 2881 gagtctctgt aaattttgg ccaaggtaaa tggaggtat ccaagatcct tccactgtg
 2941 gtatgaggag gctttgaaag atgaggaaga gagacccag gacagaattt ccaccacaga

10/16

3001 tgatactact gccatggcca gtgcaaggttc tagcgctaca ggttagcttot cctaccctga
3061 ataaaagtaag acagattctt cactgtgtt taaaaggcaa gtcaaatacc acatgatttt
3121 actcatatgt ggaatctaaa aaaaaaaaaaa aaaaaagttg gtatcatgga agtagagagt
3181 agagcagtag ttacattaca attaaatagg aggaataagt tctagtgttc tattgcacag
3241 taggatgact atagttaca ttaagatatt gtatattaca aaacagctag aaggaaggct
3301 tttcaatatt gtcacccaaa agaaatgata aatgcattgag gtgatggata cactacctga
3361 tttgatcatt atactacata tacatgaatc agaacatcaa attgtacctc ataaatatct
3421 acaattacat gtcagtttt gtttatgtt ttgtttttt ttaatttatg aaaacaaatg
3481 agaatggaaa tcaatgatgt atgtggtgga

Fig. 9 continued

11/16

SEQ ID NO. 4

Fig. 10a

TCCGGGGTCG	CTCGAGCCGG	CCGGGACTCG	GGGATCASA	GTAAACGGCGG	50
YYMKYGTKCT	GAGGGACAGG	CTTGAGATCG	GCTGAAGAGA	GCGGGCCAG	100
GCTCTGTGAG	GAGGCAAGGG	AGGTGAGAAC	CTTGCTCTCA	GAGGGTGACT	150
CAAGTCAACA	CAGGGAACCC	CTCTTTCTA	CAGACACAGT	GGGTGCGAGG	200
ATCTGACAAG	AGTCCAGGTT	CTCAGGGGAC	AGGGAGAGCA	AGAGGTCAAG	250
AGCTGTGGGA	CACCACAGAG	CAGCACTGAA	GGAGAAGACC	TGCCTGTGGG	300
TCCCCATCGC	CCAAGTCCTG	CCCACACTCC	CACCTGCTAC	CCTGATCAGA	350
GTCATCATGC	CTCGAGCTCC	AAAGCGTCAG	CGCTGCATGC	CTGAAGAAGA	400
TCTTCAATCC	CAAAGTGAGA	CACAGGGCCT	CGAGGGTGCA	CAGGCTCCCC	450
TGGCTGTGGA	GGAGGGATGCT	TCATCATCCA	CTTCCACCAG	CTCCTCTTT	500
CCATCCTCTT	TTCCCTCCTC	CTCCTCTTCC	TCCTCCTCCT	CCTGCTATCC	550
TCTAATACCA	AGCACCCCCAG	AGGAGGTTTC	TGCTGATGAT	GAGACACCAA	600
ATCCTCCCCA	GAGTGCTCAG	ATAGCCTGCT	CCTCCCCCTC	GGTCGTTGCT	650
TCCCTTCCAT	TAGATCAATC	TGATGAGGGC	TCCAGCAGCC	AAAAGGAGGA	700
GAGTCCAAGC	ACCCTACAGG	TCCTGCCAGA	CAGTGAGTCT	TTACCCAGAA	750
GTGAGATAGA	TGAAAAGGTG	ACTGATTGG	TGCAGTTCT	GCTCTTCAG	800
TATCAAATGA	AGGAGCCGAT	CACAAAGGCA	GAAATACTGG	AGAGTGTAT	850
AAAAAATTAT	GAAGACCAC	TCCCTTGTT	GTITAGTGAA	GCCTCCGAGT	900
GCATGCTGCT	GGTCTTTGGC	ATTGATGTAA	AGGAAGTGG	TCCCACGGC	950
CACTCCTTG	TCCTTGTAC	CTCCCTGGC	CTCACCTATG	ATGGGATGCT	1000
GAGTGATGTC	CAGAGCATGC	CCAAGACTGG	CATTCTCATA	CTTATCCTAA	1050
GCATAATCTT	CATAGAGGGC	TACTGCACCC	CTGAGGAGGT	CATCTGGAA	1100
GCACTGAATA	TGATGGGGCT	GTATGATGGG	ATGGAGCACC	TCATTTATGG	1150
GGAGCCCAGG	AAGCTGCTCA	CCCAAGATTG	GGTGCAGGAA	AACTACCTGG	1200
AGTACCGGCA	GGTGCCTGGC	AGTGATCTG	CACGGTATGA	GTTCCTGTGG	1250
GGTCCAAGGG	CTCATGCTGA	AATTAGGAAG	ATGAGTCTCC	TGAAATTTT	1300
GGCCAAGGTA	AATGGGAGTG	ATCCAAGATC	CTTCCCCTG	TGGTATGAGG	1350
AGGCTTGAA	AGATGAGGAA	GAGAGAGCCC	AGGACAGAAT	TGCCACCA	1400
GATGATACTA	CTGCCATGGC	CAGTGCAAGT	TCTAGCGCTA	CAGGTAGCTT	1450
CTCCTACCT	GAATAAGTA	AGACAGATTG	TTCACTGTGT	TTTAAAAGGC	1500
AAGTCAAATA	CCACATGATT	TTACTCATAT	GTGGAATCTA	AAAAAAAAAA	1550
AAAAAAAAGT	TGGTATCATG	GAAGTAGAGA	GTAGAGCAGT	AGTTACATTA	1600
CAATTAAATA	GGAGGAATAA	GTTCTAGTGT	TCTATTGCAC	AGTAGGATGA	1650
CTATAGTTAA	CATTAAGATA	TTGTATATTA	CAAAACAGCT	AGAAGGAAGG	1700
CTTTCAATA	TTGTCAACAA	AAAGAAATGA	TAAATGCATG	AGGTGATGGA	1750

12/16

TACACTACCT GATGTGATCA TTATACTACA TATACATGAA TCAGAACATC	1800
AAATTGTACC TCATAAATAT CTACAATTAC ATGTCAGTTT TTGTTTATGT	1850
TTTGTTTT TTTAATTAA TGAAAACAAA TGAGAATGGA AATCAATGAT	1900
GTATGTGGTG GAGGCCAGG CTGAGGCTGA GGAAAATACA GTGCATAACA	1950
TCTTGTCTT ACTGTTTCT TTGGATAACC TGGGGACTTC TTTCTTTTC	2000
TTCTGGTAT TTTATTCTT TTTCTTCTT CTTCTTTTT TTTTTAAACA	2050
AAGTCTCACT CTATTGCTCT GGCAGGAGTG CAGTGGTGCA GTCTCGGCTC	2100
ACTGCAACTT CCGCCTCCTG GGTTCAAGCG ATTCTCCTGC CTCAGTCTCC	2150
TGAGTAGCTG GGATTACAAG TGTGCACCAC CATAACCGGC TAATTTGTA	2200
TTTTTAGTA GAGATGGGT TTCACCATGT TGGCCAGGCT GGTCTCAAAC	2250
TCCTGACCTC AGGTAATCTG CCCGCCTCAG CCTCCCAAAG TGCTGGGATA	2300
ACAGGTGTGA GCCCACTGCA CCCCAGCCTC TTCTTGGTAT TTTAAAATGT	2350
GTACTTTT ACTAGAACAG TTATGAGCTT CAGAACATCAA GGTACACACGT	2400
CGTTTCTGT TTATCCAGTT TAAGAACAG TTTGCTATT TTGTAAAACA	2450
AATTGGGAAC CCTTCCATCA TATTTGTAAT CTTAATAAA ATAACATGGA	2500
ATTGGAATAG TAATTTCTT GGAAATATGA AAAAATAGTA AAATAGAGAA	2550
AATAATT	2559

Fig. 10b

13/16

SEQ ID NO. 5

Fig. 11a

1 agtctcagat cactggagag aggtgccccca gagcccttaa ggaggactca gcagacctcc
 61 catcatggcc taggaaacct gctcccactc tcaggtctgg gcacccaagg caggacagtg
 121 gggaaaggat gtggcccccc cactttctgg taggggggc tcaaggagat ggtggccttg
 181 gcatgcaaga cacatccacg gttcagcagg aaggaaaggg ccatgccttg tcgtggagta
 241 aatatgaata cctggatgac acccagacag agaaaagaccc catgaaacctt actacttctg
 301 tcagccgtgg gaatcccattc cagggttgc catgttagtgc ctcccttactt ctgcctcctg
 361 ggtctcaggg aggttagcaac ctgggtctga agggcgtcct cagctcagca gagggagcca
 421 cacctgttca acagaggac ggggtcacag gatctgcagg acccaagatg tgctcacttt
 481 gtgatgaatg ggggtactcc tggcctggaa agaaggaccc ccacaaagtc tggctaactt
 541 tggttattat ctctggggaa acccgatcaa gggtggccct aagtggagat ctcatctgt
 601 ctgtgggcag gaagttgggg aaacgcagga agataaggc ttggttgtaa ggggagatgt
 661 ctgctcatat cagggtgttg tgggttgcagg aaggggcgggc tccatcaggg gaaagatgaa
 721 taacccctg aagaccttag aacccaccac tcaagaacaa gtagggacag atcctagtgt
 781 caccctgga caccctaccc agtggtcattc agatgtgggt gctcctcatt tctctcttga
 841 gtctcaggga agtgaggacc ttgttctcag agggcaactc aggacaaaac agggacccccc
 901 atgtggcCAA cagactcagt ggtccaagaa tctaccaaga gtcttaggtga caacactgag
 961 ggaagattga gggtacccctc gatggttctc ctacgcaggca aaaaacagat gggggcccaa
 1021 cagaaatctg cccggcctct tttgtcaccc ctgagagcat gagcaggact atcagctgag
 1081 gcccctgtgt tataccagac tcattggctc cagggagaag aaggccttgg tctgagggca
 1141 ctgcattcag gtcagcagag cgggggtcca agggcctgcc aggagtcagg gactcagagg
 1201 acaccactca ccaaacacac aggaccgaac cccacccctgc accttctgtc agccatggga
 1261 agtgcaggga aaggtgggtg gatggaatcc cctcatttgc tcttccagtg tctcctggag
 1321 ataggcctt ggattaagga agtggcctca ggtcagccca ggacacatgg gccccatgt
 1381 attttgtgta gctattgttt ttttctcacc cttaggacaga cacgtgggccc ccattgcatt
 1441 ttgtgttagct attgctttt tcccaggagg ctttggcat gtggggccag atgtgggtcc
 1501 cttcatatcc ttgttctcca tatcagggtt ataaaacttt gatctgaaag tttctcaggc
 1561 cagcaaaagg gccagatcca ggccctgcca ggagaaagat gagggccctg aatgagcaca
 1621 gaaaggacca tccacacaaa atagtgggg gctcacagag tcaggctcac cctcctgaca
 1681 gcactgggt gctgggctg tgcttcagtg ctgcagcctg agtccccctc gatttatctt
 1741 cttaggagctc caggaaccag gctgtgaggt ctttgtctga ggcagtatct tcaatcacag
 1801 agcataagag gcccaggcag tagtagcagt caagctgagg tgggtttcc cctgtatgt
 1861 taccagaggc ccctctggca tcagaacagc aggaacccca cagttctgg ccctaccagc
 1921 cttttgtca gtcctggagc cttggcctt gccaggaggc tgccacccctga gatgccctct
 1981 caatttctcc ttcaggttgc cagagaacag gccagccagg aggtcaggag gccccagaga
 2041 agcactgaag aagacctgta agtagacctt tggtagggca tccagggtgt agtacccagc
 2101 tgaggcctct cacacgcttc ctctctcccc aggccgttgg gtctcaattt cccagctccg
 2161 gcccacactc tcctgctgcc ctgacctgag tcattcatgt tcttgggcag aagagtccgc
 2221 gctacaaggc tgaggaaggc cttcaggccc aaggagaggc accagggtt atggatgtgc
 2281 agattccac agctgaggag cagaaggctg catcctcctc ctctactctg atcatgggaa
 2341 cccttgagga ggtgactgt tctgggtcac caagtcctcc ccagagtcct gagggtgcc
 2401 cctcttccct gactgtcacc gacagcactc tggagccca atccgatgag ggttccagca
 2461 gcaatgaaga ggaggggcca agcacctccc cgacccagc tcacctggag tccctgttcc
 2521 gggaaaggact tgatgagaaa gtggctgagt tagttcggtt cctgctccgc aaatatcaaa
 2581 ttaaggagcc ggtcacaaag gcagaaatgc ttgagagtgt cataaaaat tacaagaacc
 2641 actttctgtc tatcttcagc aaagcctctg agtgcattgtca ggtgatctt ggcattgt
 2701 tgaaggaagt ggaccctgca ggccactcct acatccttgt cactgcctg ggctctcct
 2761 atgatggcct gctgggtgt gatcagagta cgcccaagac cgccctcctg ataatcgatcc

14/16

2821 tgggcatgat cttaatggag ggcagcccgccccggagga ggcaatctgg gaagcattga
2881 gtgttatgggg ggctgtatga tgggagggag cacagtgtct attggaaagct caggaagctg
2941 ctcacccaag agtgggtgca ggagaactac ctggagtacc gccaggcgcc cgccagtgtat
3001 cctgtgcgt acgagttcct gtggggtcca agggcccttgc taaaaccag ctatgtgaaa
3061 gtcctggagc atgtggtcag ggtcaatgca agagttcgca ttccctaccc atccctgcata
3121 gaagaggcctt tgggagagga gaaaggagtt tgagcaggag ttgcagctag ggccagtgg
3181 gcagggttg ggagggcctg ggccagtgcac cgttccaggg ccacatccac cactttccct
3241 gctctgttac atgaggccc ttcttcactc tgtgtttgaa gagagcagtc acagttctca
3301 gtagtgggg gcatgttggg tgtgaggagaa cacagtgtgg accatcttc agttcctgtt
3361 ctattggcg atttggaggt ttatcttgc ttccctttgg aattgttcca atgttccttc
3421 taatggatgg tgtaatgaac ttcaacattc attttatqta tgacagtaga cagacttact
3481 gcttttata tagtttagga gtaagagtct tgctttcat ttatactggg aaacccatgt
3541 tatttcttga attcagacac tacaagagca gaggattaag gtttttttag aatgtgaaa
3601 caacatagca gtaaaataca tgagataaag acataaagaa attaaacaat agttaattct
3661 tgccttacct gtaccttta gtgtacccta tgtacctgaa ttgccttggc ttctttgaga
3721 atgaaattga attaaatatg aataaataag tccccctgct cactggctca tttttccca
3781 aaatattcat tgagcttccg ctatttggaa ggcctgggt tagtatttggaa gatgctaca

Fig. 11b

15/16

SEQ ID NO. 6

GAGCTCCAGG	AACCAGGCTG	TGAGGTCTTG	GTCTGAGGCA	GTATCTCAA	50
TCACAGAGCA	TAACAGGCC	AGGCAGTAGT	AGCAGTCAAG	CTGAGGTGGT	100
GTTCCCCCTG	TATGTATAACC	AGAGGCCCC	CTGGCATCAG	AACAGCAGGA	150
ACCCCACAGT	TCCTGGCCCT	ACCAGCCCTT	TTCTCAGTCC	TGGAGCCTTG	200
GCCTTGGCCA	GGAGGCTGCA	CCCTGAGATG	CCCTCTCAAT	TTCTCCTTCA	250
GGTTCGCAGA	GAACAGGCCA	GCCAGGAGGT	CAGGAGGCC	CAGAGAAGCA	300
CTGAAGAAGA	CCTGTAAGTA	GACCTTTGTT	AGGGCATCCA	GGGTGTAGTA	350
CCCAGCTGAG	GCCTCTCAC	CGCTTCCCTCT	CTCCCCAGGC	CTGTGGGTCT	400
CAATTGCCCA	GCTCCGGCCC	ACACTCTCT	GCTCCCCCTGA	CCTGAGTCAT	450
C					451
ATG CTT CTT	GGG CAG AAG	AGT CAG CGC	TAC AAG GCT	GAG GAA	493
GGC CTT CAG	CCC CAA CGA	GAG CCA CCA	GGG CTT ATG	GAT GTG	535
CAG ATT CCC	ACA CCT GAG	GAG CAG AAG	GCT CCA TCC	TCC TCC	577
TCT ACT CTG	ATC ATG GGA	ACC CTG GAG	GAG GTG ACT	GAT TCT	619
GGG TCA CCA	AGT CCT CCC	CAG AGT CCT	GAG GGT GCC	TCC TCT	661
TCC CTG ACT	GTC ACC GAC	AGC ACT CTG	TGG AGC CAA	TCC GAT	703
GAG GGT TCC	AGC AGC AAT	GAA GAG GAG	GGG CCA AGC	ACC TCC	745
CCG GAC CCA	GCT CAC CTG	GAG TCC CTG	TTC CGG GAA	GCA CTT	787
GAT GAG AAA	GTG CCT GAG	TTA GTT CCG	TTC CTG CTC	CGC AAA	829
TAT CAA ATT	AAG GAG CCG	GTC ACA AAG	GCA GAA ATG	CTT GAG	871
AGT GTC ATC	AAA AAT TAC	AAG AAC CAC	TTT CCT GAT	ATC TTC	913
AGC AAA GCC	TCT GAG TGC	ATG CAG GTG	ATC TTT GGC	ATT GAT	955
GTG AAG GAA	GTG GAC CCT	CCC CCC CAC	TCC TAC ATC	CTT GTC	997
ACC TCC CTG	GGC CTC TCC	TAT CAT GGC	CTG CTG GGT	GAT GAT	1039
CAG AGT ACG	CCC AAG ACC	GGC CTC CTG	ATA ATC GTC	CTG GGC	1081
ATG ATC TTA	ATG GAG GGC	AGC CGC CCC	GAG GAG GCA	ATC	1123
TGG CAA GCA	TTG AGT GTG	ATG GGG GCT	GTA TGA	TGA	1156
TGGCAGGGAG	CACAGTCTCT	ATTGGAAGCT	CAGGAAGCTG	CTCACCCAAAG	1206
AGTGGGTCCA	GGAGAACTAC	CTGGAGTACC	GCCAGGCC	CGGCAGTGAT	1256
CCTGTGGCT	ACGAGTTCT	GTGGGGTCCA	AGGGCCCTTG	CTGAAACCAAG	1306
CTATGTAAA	GTCCTGGAGC	ATGTGGTCAG	GGTCAATCCA	AGAGTTGCCA	1356
TTTCTACCC	ATCCCTGCAT	GAACAGGCTT	TGGGAGAGGA	AAAAGGAGTT	1406
TGAGCAGGAG	TTGCAGCTAG	GGCCAGTGGG	GCAGGTTGTC	GGAGGGCTG	1456
GGCCAGTCCA	CGTCCAGGG	CCACATCCAC	CACTTTCCCT	GCTCTGTTAC	1506
ATGAGGCCA	TTCTTCACTC	TGTGTTGAA	GAGAGCAGTC	ACAGTTCTCA	1556
GTAGTGGGA	GCATGTTGGG	TGTGAGGGAA	CACAGTGTGG	ACCATCTCTC	1606
AGTTCTGTT	CTATTGGGCC	ATTGGAGGT	TTATCTTGT	TTCCCTTTGG	1656
ATTGTTCCA	ATGTTCTTC	TAATGGATGG	TGTAATGAA	TTCAACATTC	1706
ATTTATGTA	TGACAGTAGA	CAGACTTACT	GCTTTTATA	TAGTTTAGGA	1756
GTAAAGACTCT	TCCTTTCAT	TTATACTGGG	AAACCCATGT	TATTTCTTGA	1806
ATTC					1810

Fig. 12

16/16

SEQ ID NO. 7

ACCTGCTCCA	GGACAAAGTG	GACCCCCTG	CATCAGCTCC	ACCTACCCCTA	50
CTGTCAGTCC	TGGAGCCTTC	GCCTCTGCCG	GCTGCATCCT	GAGGAGCCAT	100
CTCTCACTTC	CTTCTTCAGG	TTCTCAGGGG	ACAGGGAGAG	CAAGAGGTCA	150
AGAGCTGTGG	CACACCACAG	AGCAGGACTG	AAGGAGAAGA	CCTGTAAGTT	200
GGCCTTTGTT	AGAACCTCCA	GGGTGTGCTT	CTCAGCTGTG	GCCACTTACA	250
CCCTCCCTCT	CTCCCCAGGC	CTGTGGGTCC	CCATCCCCA	AGTCCTGCC	300
ACACTCCCCAC	CTGCTACCCCT	GATCAGAGTC	ATC		333
ATG CCT CCA GCT CCA AAG CGT CAG CGC TGC ATG CCT GAA GAA					375
GAT CTT CAA TCC CAA AGT GAG ACA CAG GGC CTC GAG GGT GCA					417
CAG GCT CCC CTG GCT GTG GAG GAG GAT GCT TCA TCA TCC ACT					459
TCC ACC AGC TCC TCT TTT CCA TCC TCT TTT CCC TCC TCC TCC					501
TCT TCC TCC TCC TCC TCC TGC TAT CCT CTA ATA CCA AGC ACC					543
CCA GAG GAG GTT TCT GCT GAT GAT GAG ACA CCA AAT CCT CCC					585
CAG AGT GCT CAG ATA GCC TGC TCC TCC CCC TCG GTC CTT GCT					627
TCC CTT CCA TTA GAT CAA TCT GAT GAG GGC TCC AGC AGC CAA					669
AAG GAG CAG AGT CCA AGC ACC CTA CAG GTC CTG CCA GAC AGT					711
GAG TCT TTA CCC AGA AGT GAG ATA GAT GAA AAG GTG ACT GAT					753
TTG GTG CAG TTT CTG CTC TTC AAG TAT CAA ATG AAG GAG CCG					795
ATC ACA AAG GCA GAA ATA CTG GAG ACT GTC ATA AAA AAT TAT					837
GAA GAC CAC TTC CCT TTG TTG TTT AGT GAA GCC TCC GAG TGC					879
ATC CTG CTG GTC TTT CGC ATT GAT GTA AAG GAA GTG GAT CC					920

Fig. 13

-1-

SEQUENCE LISTING

<110> Ludwig Institute For Cancer Research

<120> Tumour rejection antigens

<130> TSJ/34953

<140>

<141>

<150> GB 9826143.1

<151> 1998-11-27

<160> 56

<170> PatentIn Ver. 2.1

<210> 1

<211> 369

<212> PRT

<213> Homo sapiens

<400> 1

Met Pro Arg Ala Pro Lys Arg Gln Arg Cys Met Pro Glu Glu Asp Leu
1 5 10 15

Gln Ser Gln Ser Glu Thr Gln Gly Leu Glu Gly Ala Gln Ala Pro Leu
20 25 30

Ala Val Glu Glu Asp Ala Ser Ser Ser Thr Ser Thr Ser Ser Phe
35 40 45

Pro Ser Ser Phe Pro Ser Ser Ser Ser Ser Ser Ser Cys Tyr
50 55 60

Pro Leu Ile Pro Ser Thr Pro Glu Glu Val Ser Ala Asp Asp Glu Thr
65 70 75 80

Pro Asn Pro Pro Gln Ser Ala Gln Ile Ala Cys Ser Ser Pro Ser Val
85 90 95

Val Ala Ser Leu Pro Leu Asp Gln Ser Asp Glu Gly Ser Ser Ser Gln
100 105 110

Lys Glu Glu Ser Pro Ser Thr Leu Gln Val Leu Pro Asp Ser Glu Ser
115 120 125

Leu Pro Arg Ser Glu Ile Asp Glu Lys Val Thr Asp Leu Val Gln Phe
130 135 140

Leu Leu Phe Lys Tyr Gln Met Lys Glu Pro Ile Thr Lys Ala Glu Ile
145 150 155 160

-2-

Leu Glu Ser Val Ile Lys Asn Tyr Glu Asp His Phe Pro Leu Leu Phe
165 170 175

Ser Glu Ala Ser Glu Cys Met Leu Leu Val Phe Gly Ile Asp Val Lys
180 185 190

Glu Val Asp Pro Thr Gly His Ser Phe Val Leu Val Thr Ser Leu Gly
195 200 205

Leu Thr Tyr Asp Gly Met Leu Ser Asp Val Gln Ser Met Pro Lys Thr
210 215 220

Gly Ile Leu Ile Leu Ile Leu Ser Ile Ile Phe Ile Glu Gly Tyr Cys
225 230 235 240

Thr Pro Glu Glu Val Ile Trp Glu Ala Leu Asn Met Met Gly Leu Tyr
245 250 255

Asp Gly Met Glu His Leu Ile Tyr Gly Glu Pro Arg Lys Leu Leu Thr
260 265 270

Gln Asp Trp Val Gln Glu Asn Tyr Leu Glu Tyr Arg Gln Val Pro Gly
275 280 285

Ser Asp Pro Ala Arg Tyr Glu Phe Leu Trp Gly Pro Arg Ala His Ala
290 295 300

Glu Ile Arg Lys Met Ser Leu Leu Lys Phe Leu Ala Lys Val Asn Gly
305 310 315 320

Ser Asp Pro Arg Ser Phe Pro Leu Trp Tyr Glu Glu Ala Leu Lys Asp
325 330 335

Glu Glu Glu Arg Ala Gln Asp Arg Ile Ala Thr Thr Asp Asp Thr Thr
340 345 350

Ala Met Ala Ser Ala Ser Ser Ala Thr Gly Ser Phe Ser Tyr Pro
355 360 365

Glu

<210> 2
<211> 234
<212> PRT
<213> Homo sapiens

<400> 2
Met Leu Leu Gly Gln Lys Ser Gln Arg Tyr Lys Ala Glu Glu Gly Leu
1 5 10 15

Gln Ala Gln Gly Glu Ala Pro Gly Leu Met Asp Val Gln Ile Pro Thr
20 25 30

-3-

Ala Glu Glu Gln Lys Ala Ala Ser Ser Ser Ser Thr Leu Ile Met Gly
35 40 45

Thr Leu Glu Glu Val Thr Asp Ser Gly Ser Pro Ser Pro Pro Gln Ser
50 55 60

Pro Glu Gly Ala Ser Ser Ser Leu Thr Val Thr Asp Ser Thr Leu Trp
65 70 75 80

Ser Gln Ser Asp Glu Gly Ser Ser Ser Asn Glu Glu Gly Pro Ser
85 90 95

Thr Ser Pro Asp Pro Ala His Leu Glu Ser Leu Phe Arg Glu Ala Leu
100 105 110

Asp Glu Lys Val Ala Glu Leu Val Arg Phe Leu Leu Arg Lys Tyr Gln
115 120 125

Ile Lys Glu Pro Val Thr Lys Ala Glu Met Leu Glu Ser Val Ile Lys
130 135 140

Asn Tyr Lys Asn His Phe Pro Asp Ile Phe Ser Lys Ala Ser Glu Cys
145 150 155 160

Met Gln Val Ile Phe Gly Ile Asp Val Lys Glu Val Asp Pro Ala Gly
165 170 175

His Ser Tyr Ile Leu Val Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu
180 185 190

Leu Gly Asp Asp Gln Ser Thr Pro Lys Thr Gly Leu Leu Ile Ile Val
195 200 205

Leu Gly Met Ile Leu Met Glu Gly Ser Arg Ala Pro Glu Glu Ala Ile
210 215 220

Trp Glu Ala Leu Ser Val Met Gly Ala Val
225 230

<210> 3

<211> 3510

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1955)..(3064)

<400> 3

cagggagatg gtggctttgg cgtgcaggac ccatacacga ttccagcagga gggaaaggct 60
gggctgtcg gactaaatct gaataacctgg aggacaccca aataaaggaa gtccccgtct 120
tgtccccctc ccctgcccac cacccccccc ccccccggca aatgtctgct cttctgtca 180

-4-

gctttggaa tcccatgcag gtgtgatcgt gtggtcccc tccccacttc tgccctgccg 240
 gtctcaaggaa ggtgaggacc ttggctcgag gggtgctaag aagtattac agggtccac 300
 acttggtaa cagagggagg agtcccagaa tctgcaggac ccaaggggtg ccccttagt 360
 gaggactgga ggtacctgca gcccagaaag aagggatgtc acagagtctg gctgtccc 420
 gttcttagct ctgaggggac ctgatcagga ttggcactaa gtggcaagct caatttacc 480
 acaggcagga agatgaggaa ccctcaggaa aatggagtt tgggtaaag gggagatatac 540
 agccctggac accccacagg gatgacagga tggctccct tcttactttt gtttggaaat 600
 ctcagggagg tgagaacctt gctctcagag ggtgactcaa gtcaacacag ggaacccctc 660
 ttttctacag acacagtggg tcgcaggatc tgacaagagt ccaggttaagg aacctgaggg 720
 aaatctgagg gtaccccccag cccataaacac agatgggtc cccacagaaa tctgccatga 780
 ccctactgtc actctggaga acccagtctg ggctgtccgc tgagtctccc tgtcttatac 840
 aaggatcaact ggtctctggg agggagaggt gttggctaa gggagctgca ctcgggtcag 900
 cagagggagg gtcccagacc ctgcaggag tcaaggtagg gactgagggg acaccattct 960
 ccaaacgcac aggactcagc cccaccctac cccttctgtc agccacggga attcatgggg 1020
 aactgggggt agatggactc ccctcacttc ctcttccat gtctctggg gtagggacct 1080
 tggtttaagg aagtggcctc agatcaacaa agggagggtc ccaggtcgta tcaggcatca 1140
 agaagaggac caagcaggct ctcacccca gtacacatgg acccagctga atatggccac 1200
 cttttgcgtc cttttctggg aggacctctg cagttgtggc cagatgtggg tcccctcatg 1260
 tcttcttattt cgtatcaggg atgtaagctt ttgatctgag agtttcttag accagcaaag 1320
 gagcagggtc taggctttc caggagaaag gtgagagccc cacgtgagca cagaggctcc 1380
 ccaccccagg gtagtgggaa actcacagag tccagccac cctcctgaca acactggag 1440
 gctggggctg tgcttcagc ctgaacccctg agggccccc aatttctctt tcaggagctc 1500
 cagggactgt gaggtgaggc cttgtctaa ggcaatgttt tcaggtcaca gacgagaaag 1560
 ggcggcagaca gtgccaggag tcaaggtagg gtgcatgccc tgaatgtgta ccaagggccc 1620
 cacctgcctc aggacaaagt ggacccact gcatcagctc cacctaccct actgtcagtc 1680
 ctggagccctt ggcctctgcc ggctgcattc tgaggagcca tctctcaattt ctttcttcag 1740
 gttctcaggg gacagggaga gcaagaggctc aagagctgtg ggacaccaca gacgacact 1800
 gaaggagaag acctgttaagt tggctttgt tagaacctcc aggtgtggt tctcagctgt 1860
 ggccacttac accctccctc totccccagg cctgtggtc cccatcgccc aagtccctgcc 1920

cacactccca cctgctaccc tgatcagagt catc atg cct cga gct cca aag cgt 1975
 Met Pro Arg Ala Pro Lys Arg
 1 5

cag cgc tgc atg cct gaa gaa gat ctt caa tcc caa agt gag aca cag 2023
 Gln Arg Cys Met Pro Glu Glu Asp Leu Gln Ser Gln Ser Glu Thr Gln
 10 15 20

ggc ctc gag ggt gca cag gct ccc ctg gct gtg gag gag gat gct tca 2071
 Gly Leu Glu Gly Ala Gln Ala Pro Leu Ala Val Glu Glu Asp Ala Ser
 25 30 35

tca tcc act tcc acc agc tcc tct ttt cca tcc tct ttt ccc tcc tcc 2119
 Ser Ser Thr Ser Thr Ser Ser Phe Pro Ser Ser Phe Pro Ser Ser
 40 45 50 55

tcc tct tcc tcc tcc tcc tgc tat cct cta ata cca agc acc cca 2167
 Ser Ser Ser Ser Ser Ser Cys Tyr Pro Leu Ile Pro Ser Thr Pro
 60 65 70

gag gag gtt tct gct gat gat gag aca cca aat cct ccc cag agt gct 2215
 Glu Glu Val Ser Ala Asp Asp Glu Thr Pro Asn Pro Pro Gln Ser Ala
 75 80 85

-5-

cag ata gcc tgc tcc tcc ccc tcg gtc gtt gct tcc ctt cca tta gat	2263
Gln Ile Ala Cys Ser Ser Pro Ser Val Val Ala Ser Leu Pro Leu Asp	
90	95
	100
caa tct gat gag ggc tcc agc agc caa aag gag gag gag agt cca agc acc	2311
Gln Ser Asp Glu Gly Ser Ser Gln Lys Glu Glu Ser Pro Ser Thr	
105	110
	115
cta cag gtc ctg cca gac agt gag tct tta ccc aga agt gag ata gat	2359
Leu Gln Val Leu Pro Asp Ser Glu Ser Leu Pro Arg Ser Glu Ile Asp	
120	125
	130
	135
gaa aag gtg act gat ttg gtg cag ttt ctg ctc ttc aag tat caa atg	2407
Glu Lys Val Thr Asp Leu Val Gln Phe Leu Leu Phe Lys Tyr Gln Met	
140	145
	150
aag gag ccg atc aca aag gca gaa ata ctg gag agt gtc ata aaa aat	2455
Lys Glu Pro Ile Thr Lys Ala Glu Ile Leu Glu Ser Val Ile Lys Asn	
155	160
	165
tat gaa gac cac ttc cct ttg ttg ttt agt gaa gcc tcc gag tgc atg	2503
Tyr Glu Asp His Phe Pro Leu Leu Phe Ser Glu Ala Ser Glu Cys Met	
170	175
	180
ctg ctg gtc ttt ggc att gat gta aag gaa gtg gat ccc act ggc cac	2551
Leu Leu Val Phe Gly Ile Asp Val Lys Glu Val Asp Pro Thr Gly His	
185	190
	195
tcc ttt gtc ctt gtc acc tcc ctg ggc ctc acc tat gat ggg atg ctg	2599
Ser Phe Val Leu Val Thr Ser Leu Gly Leu Thr Tyr Asp Gly Met Leu	
200	205
	210
	215
agt gat gtc cag agc atg ccc aag act ggc att ctc ata ctt atc cta	2647
Ser Asp Val Gln Ser Met Pro Lys Thr Gly Ile Leu Ile Leu Ile Leu	
220	225
	230
agc ata atc ttc ata gag ggc tac tgc acc cct gag gag gtc atc tgg	2695
Ser Ile Ile Phe Ile Glu Gly Tyr Cys Thr Pro Glu Glu Val Ile Trp	
235	240
	245
gaa gca ctg aat atg atg ggg ctg tat gat ggg atg gag cac ctc att	2743
Glu Ala Leu Asn Met Met Gly Leu Tyr Asp Gly Met Glu His Leu Ile	
250	255
	260
tat ggg gag ccc agg aag ctg ctc acc caa gat tgg gtg cag gaa aac	2791
Tyr Gly Glu Pro Arg Lys Leu Leu Thr Gln Asp Trp Val Gln Glu Asn	
265	270
	275
tac ctg gag tac cgg cag gtg cct ggc agt gat cct gca cgg tat gag	2839
Tyr Leu Glu Tyr Arg Gln Val Pro Gly Ser Asp Pro Ala Arg Tyr Glu	
280	285
	290
	295

-6-

ttt ctg tgg ggt cca agg gct cat gct gaa att agg aag atg agt ctc	2887
Phe Leu Trp Gly Pro Arg Ala His Ala Glu Ile Arg Lys Met Ser Leu	
300	305
	310
ctg aaa ttt ttg gcc aag gta aat ggg agt gat cca aga tcc ttc cca	2935
Leu Lys Phe Leu Ala Lys Val Asn Gly Ser Asp Pro Arg Ser Phe Pro	
315	320
	325
ctg tgg tat gag gag gct ttg aaa gat gag gaa gag aga gcc cag gac	2983
Leu Trp Tyr Glu Ala Leu Lys Asp Glu Glu Arg Ala Gln Asp	
330	335
	340
aga att gcc acc aca gat gat act act gcc atg gcc agt gca agt tct	3031
Arg Ile Ala Thr Thr Asp Asp Thr Thr Ala Met Ala Ser Ala Ser Ser	
345	350
	355
agc gct aca ggt agc ttc tcc tac cct gaa taa agtaagacag attcttcact	3084
Ser Ala Thr Gly Ser Phe Ser Tyr Pro Glu	
360	365
	370
gtgtttaaaa aggcaagtca aataccacat gattttactc atatgtggaa tctaaaaaaaa	3144
aaaaaaaaaa aagtttgtat catgaaagta gagagtagag cagtagttac attacaatta	3204
aataggagga ataagttcta gtgttctatt gcacagtagg atgactatag ttaacattaa	3264
gatattgtat attacaaaac agctagaagg aaggctttc aatattgtca ccaaaaagaa	3324
atgataaaatg catgaggtga tggatacact acctgatttg atcattatac tacatataca	3384
tgaatcagaa catcaaattg tacctataa atatctacaa ttacatgtca gttttgttt	3444
atgtttttgt ttttttttaa ttatgaaaa caaatgagaa tggaaatcaa tgatgtatgt	3504
	3510

<210> 4
<211> 2559
<212> DNA
<213> Homo sapiens

<400> 4

tccgggggtcg ctcgagccgg ccgggactcg gggatcasaa gtaacggcgg yymkygtkct	60
gagggacagg cttgagatcg gctgaagaga gcgggcccag gctctgtgag gaggcaaggg	120
aggtgagaac cttgtctca gaggtgtact caagtcaaca caggaaaccc ctctttcta	180
cagacacagt gggtcgcagg atctgacaag agtccaggtt ctcaggggac agggagagca	240
agaggtcaag agctgtggg caccacagag cagcactgaa ggagaagacc tgcctgtgg	300
tccccatcgc ccaagtccctg cccacactcc cacctgctac cctgatcaga gtcatcatgc	360
ctcgagctcc aaagcgtcag cgctgcatgc ctgaagaaga tttcaatcc caaagtgaga	420
cacagggcct cgaggggtgca caggtcccc tggctgtgga ggaggatgt tcatacatcca	480
cttccaccag ctcctttt ccatectttt ttcccttc ctcctttcc tcctccct	540
cctgctatcc tctaataccca agcaaaaaag aggaggttc tgcgtatgt gagacaccaa	600
atcctccca gagtgctcag atagccgtc ctcctcc ggtcgttgc tccctccat	660
tagatcaatc tgatgagggc tccagcagcc aaaaggagga gagtccaaagc accctacagg	720
tcctgccaga cagtgagttt ttacccagaa gtgagataga taaaaagggtg actgatttg	780
tgcagtttct gctcttcaag tatcaaataa aggagccat cacaaggca gaaatactgg	840
agagtgtcat aaaaaattat gaagaccact tcccttgc gtttagtgaa gcctccgagt	900
gcatgctgct ggtcttggc attgatgtaa aggaagtggc tcccactggc cactccttgc	960

-7-

tccttgcac ctccctggc ctcacctatg atggatgct gagtgtatgc cagagcatgc 1020
ccaagactgg cattctcata cttatcctaa gcataatctt catagaggc tactgcaccc 1080
ctgaggaggt catctggaa gcactgaata ttagtgggct gtatgtatggg atggagcacc 1140
tcatttatgg ggagccagg aagctgctca cccaagattt ggtgcaggaa aactacctgg 1200
agtaccggca ggtgcctggc agtgatcctg cacggtatga gtttctgtgg ggtccaagg 1260
ctcatgctga aatttaggaag atgagtctcc tgaaattttt gccaaggta aatgggagtg 1320
atccaaagatc cttcccactg tggatgagg aggctttgaa agatgaggaa gagagagccc 1380
aggacagaat tgccaccaca gatgatacta ctgccatggc cagtgcaggat tctagcgcta 1440
caggtagctt ctccctaccct gaataaaagta agacagattt ttcaactgtgt tttaaaaggc 1500
aagtcaaata ccacatgatt ttactcatat gtggaatcta aaaaaaaaaaaaaaaaagg 1560
tggatcatg gaagtagaga gtagagcgt agttacatta caattaaata ggaggaataa 1620
gttctagtgt tctattgcac agtaggatga ctatagttaa cattaagata ttgtatattt 1680
caaaacagct agaaggaagg ctttcaata ttgtcaccaa aaagaaaatga taaatgcatt 1740
aggtgatgga tacactaccc gatgtgatca ttatactaca tatacatgaa tcagaacatc 1800
aaattgtacc tcataaaatat ctacaattac atgtcagttt ttgtttatgt ttttgggg 1860
ttttaatttta tgaaaacaaa tgagaatgga aatcaatgtat gtatgtggg gaggcccagg 1920
ctgaggctga ggaaaataca gtgcataaca tctttgtctt actgttttct ttggataacc 1980
tggggacttc ttttcttttct ttcttggat ttttattttct ttttcttctt cttcttttt 2040
tttttaaca aagtctcact ctattgctct ggcaggagtg cagtggtgca gtctcggtc 2100
actgcaactt ccgcctccctg gttcaagcg attctccctgc ctcaagtctcc tgagtagctg 2160
ggattacaag tggcaccac cataccggc taattttgtt ttttttagta gagatgggg 2220
ttcaccatgt tgccagggt ggtctcaaacc tcctgaccc agttaatctg cccgcctcag 2280
cctcccaaag tgctggata acagggtgtga gccactgca ccccagcctc ttcttggat 2340
tttaaaatgt tggtaactttt actagaatgt ttatgagtt cagaatctaa ggtcacacgt 2400
tcgtttctgt ttatccagtt taagaaaacag ttttgcattt ttgtaaaaca aattggaaac 2460
cctccatca tatttgaat cttaataaa ataacatgga attggaaatag taattttctt 2520
gaaaatatga aaaaatagta aaatagagaa aataatttt 2559

<210> 5
<211> 3839
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (2196)..(2900)

<400> 5
agtctcagat cactggagag aggtgccccca gagcccttaa ggaggactca gcagacctcc 60
catcatggcc taggaaacct gctccactc tcaggtctgg gcacccaaagg caggacagt 120
gggaaggat gtggccccc cacttctgg tagggggcc tcaaggagat ggtggcctt 180
gcatgcaaga cacatccacg gttcagcagg aaggaaaggcc ccatgccttgc tcgtggat 240
aatatgaata cctggatgac acccagacag agaaagaccc catgaaaccc actacttctg 300
tcagccgtgg gaatcccattt cagggttgtc catgtatgtc ctccttactt ctgcctcc 360
ggtctcaggg agtagcaac ctgggtctga agggcgctt cagctcagca gagggagcca 420
cacctgttca acagagggac ggggtcacag gatctgcagg acccaagatg tgctcaactt 480
gtgatgaatg ggggtactcc tggcctggaa agaagggacc ccacaaaagtc tggctaactt 540
tggattttt ctctggggaa acccgatcaa gggtggccct aagtggagat ctcatctgt 600
ctgtggcag gaagttgggg aaacgcagga agataaggc ttgggtgtaa ggggagatgt 660
ctgctcatat cagggtgttg tgggttgagg aaggccggc tccatcaggg gaaagatgaa 720
taaccctctg aagaccttag aaccaccac tcaagaacaa gttagggacag atcctagtt 780
cacccttggc caccaccacc agtggtcatc agatgtggtg gctcctcatt tctcttgc 840
gtctcaggaa agtgaggacc ttgttctcag agggcaactc aggacaaaac agggacccccc 900

-8-

atgtggcaa cagactcagt ggtccaagaa tctaccaaga gtcttaggtga caaacactgag 960
ggaaggattga ggttaccctc gatggttctc cttagcaggca aaaaacagat gggggcccaa 1020
cagaaatctg cccggcctct tttgtcaccc ctgagagcat gaggcaggact atcagctgag 1080
gcccctgtgt tataccagac tcattggtct cagggagaag aaggccttgg tctgagggca 1140
ctgcattcag gtcagcagag cgggggtcca aggcctgcc aggagtctgg gactcagagg 1200
acaccactca ccaaacacac aggaccgaac cccaccctgc accttctgtc agccatggaa 1260
agtgcaggaa aagggtgggtg gatggaatcc cctcatttgc tcttccagtg tctcctggag 1320
ataggcctt ggattaagga agtggcctca ggtcagccca ggacacatgg gcccccaatgt 1380
attttgtta gctattgtct ttttctcacc cttaggacaga cacgtgggccc ccattgcatt 1440
tttgttagct attgtttttt tcccaggagg ctttgggcat gtggggccag atgtgggtcc 1500
cttcataatcc ttgtcttcca tatcaggat ataaactctt gatctgaaag tttctcaggc 1560
cagcaaaagg gccagatcca ggccctgcca ggagaaaagat gagggccctg aatgagcaca 1620
gaaaggacca tccacacaaa atagtgggga gtcacagag tcaggctcac cctcctgaca 1680
gcactgggt gctggggctg tgcttgcagt ctgcagcctg agtccccctc gatttatctt 1740
cttaggagtc caggaaccag gctgtgaggt cttggctcta ggcagtatct tcaatcacag 1800
agcataagag gcccaggcgag tagtagcagt caagctgagg tgggtttcc cctgtatgt 1860
taccagggc ccctctggca tcagaacacgc aggaacccca cagttctgg ccctaccaggc 1920
cctttgtca gtcctggagc cttggcctt gccaggaggc tgcaccctga gatgcctct 1980
caatttctcc tttaggttcg cagagaacag gccagccagg aggtcaggag gccccagaga 2040
agcactgaag aagacctgtt agtagacatt ttgttagggca tccagggtgt agtaccaggc 2100
tgaggcctct cacacgcttc ctctctcccc aggccctgtgg gtctcaattt cccagctccg 2160

gcccacactc tcctgctgcc ctgacacctgag tcatc atg ctt ctt ggg cag aag 2213
Met Leu Leu Gly Gln Lys
1 5

agt cag cgc tac aag gct gag gaa ggc ctt cag gcc caa gga gag gca 2261
Ser Gln Arg Tyr Lys Ala Glu Glu Gly Leu Gln Ala Gln Gly Glu Ala
10 15 20

cca ggg ctt atg gat gtg cag att ccc aca gct gag gag cag aag gct 2309
Pro Gly Leu Met Asp Val Gln Ile Pro Thr Ala Glu Glu Gln Lys Ala
25 30 35

gca tcc tcc tcc tct act ctg atc atg gga acc ctt gag gag gtg act 2357
Ala Ser Ser Ser Ser Thr Leu Ile Met Gly Thr Leu Glu Glu Val Thr
40 45 50

gat tct ggg tca cca agt cct ccc cag agt cct gag ggt gcc tcc tct 2405
Asp Ser Gly Ser Pro Ser Pro Pro Gln Ser Pro Glu Gly Ala Ser Ser
55 60 65 70

tcc ctg act gtc acc gac agc act ctg tgg agc caa tcc gat gag ggt 2453
Ser Leu Thr Val Thr Asp Ser Thr Leu Trp Ser Gln Ser Asp Glu Gly
75 80 85

tcc agc agc aat gaa gag gag ggg cca agc acc tcc ccg gac cca gct 2501
Ser Ser Ser Asn Glu Glu Gly Pro Ser Thr Ser Pro Asp Pro Ala
90 95 100

cac ctg gag tcc ctg ttc cgg gaa gca ctt gat gag aaa gtg gct gag 2549
His Leu Glu Ser Leu Phe Arg Glu Ala Leu Asp Glu Lys Val Ala Glu
105 110 115

-9-

tta gtt cgt ttc ctg ctc cgc aaa tat caa att aag gag ccg gtc aca	2597
Leu Val Arg Phe Leu Leu Arg Lys Tyr Gln Ile Lys Glu Pro Val Thr	
120 125 130	
aag gca gaa atg ctt gag agt gtc atc aaa aat tac aag aac cac ttt	2645
Lys Ala Glu Met Leu Glu Ser Val Ile Lys Asn Tyr Lys Asn His Phe	
135 140 145 150	
cct gat atc ttc agc aaa gcc tct gag tgc atg cag gtg atc ttt ggc	2693
Pro Asp Ile Phe Ser Lys Ala Ser Glu Cys Met Gln Val Ile Phe Gly	
155 160 165	
att gat gtg aag gaa gtg gac cct gcc ggc cac tcc tac atc ctt gtc	2741
Ile Asp Val Lys Glu Val Asp Pro Ala Gly His Ser Tyr Ile Leu Val	
170 175 180	
acc tgc ctg ggc ctc tcc tat gat ggc ctg ctg ggt gat gat cag agt	2789
Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu Gly Asp Asp Gln Ser	
185 190 195	
acg ccc aag acc ggc ctc ctg ata atc gtc ctg ggc atg atc tta atg	2837
Thr Pro Lys Thr Gly Leu Leu Ile Ile Val Leu Gly Met Ile Leu Met	
200 205 210	
gag ggc agc cgc gcc ccg gag gag gca atc tgg gaa gca ttg agt gtg	2885
Glu Gly Ser Arg Ala Pro Glu Glu Ala Ile Trp Glu Ala Leu Ser Val	
215 220 225 230	
atg ggg gct gta tga tggaggagcacagtgtct attgaaagct caggaagctg	2940
Met Gly Ala Val	
235	
ctcacccaag agtgggtgca ggagaactac ctggagtagacc gccaggcgcc cggcagtgtat	3000
cctgtgcgtt acgagttccgttgggttcca agggcccttg ctgaaaccag ctatgtaaaa	3060
gtcctggagc atgtggtcag ggtcaatgca agagttcgca ttccctaccc atccctgcata	3120
gaagaggctt tggagagga gaaaggagtt tgagcaggag ttgcagctag gcccagtggg	3180
gcaggttgtg ggagggcctg ggccagtgcg cgttccaggcc acatccac cacttccct	3240
gctctgttac atgaggccca ttcttcactc tgggtttgaa gagagcagtc acagttctca	3300
gtatgtggga gcatgttggg tggaggagaa cacagtgtgg accatctctc agttctgtt	3360
ctattggcg atttggaggt ttatcttgc ttccctttgg aattgttcca atgttccctc	3420
taatggatgg tggatgttcaacatc attttatgtt tgacagtaga cagacttact	3480
gcttttata tagtttagga gtaagagtct tgcttttcat ttatactggg aaaccatgt	3540
tatttcttga attcagacac tacaagagca gaggattaag gtttttttag aatgtaaaa	3600
caacatagca gtaaaataaca tgagataaaag acataaagaa attaaacaat agttaattct	3660
tgccttacccatgttacccata ttttgcgttggc ttctttgaga	3720
atgaaatttgc attaaatatgc aataaataag tccccctgtct cactggctca tttttccca	3780
aaatatttcat tggatgttccat ggcctgggt tagtatttgc gatgttaca	3839

<210> 6
<211> 1810
<212> DNA
<213> Homo sapiens

-10-

```

<220>
<221> CDS
<222> (452)..(1153)

<400> 6
gagctccagg aaccaggctg tgaggtcttg gtctgaggca gatatcttcaa tcacagagca 60
taagaggccc aggcagtagt agcagtcaag ctgaggtgg tttccctg tatgtataacc 120
agaggccccct ctggcatcaag aacagcagga accccacagt tcctggccct accagccctt 180
ttgtcagtc tggagccttg gccttgcca ggaggctgca ccctgagatg ccctctcaat 240
ttctccttca ggttcgcaga gaacaggcca gccaggaggt caggaggccc cagagaagca 300
ctgaagaaga cctgtaagta gaccttggtt agggcatcca gggtagtca cccagctgag 360
gcctctcaca cgcttcctct cttccaggc ctgtgggtct caattgccc gctccggccc 420

acactctcct gctgccctga cctgagtcat c atg ctt ctt ggg cag aag agt      472
                           Met Leu Leu Gly Gln Lys Ser
                           1           5

cag cgc tac aag gct gag gaa ggc ctt cag gcc caa gga gag gca cca      520
Gln Arg Tyr Lys Ala Glu Glu Gly Leu Gln Ala Gln Gly Glu Ala Pro
   10          15          20

ggg ctt atg gat gtg cag att ccc aca gct gag gag cag aag gct gca      568
Gly Leu Met Asp Val Gln Ile Pro Thr Ala Glu Glu Gln Lys Ala Ala
   25          30          35

tcc tcc tcc tct act ctg atc atg gga acc ctt gag gag gtg act gat      616
Ser Ser Ser Ser Thr Leu Ile Met Gly Thr Leu Glu Glu Val Thr Asp
   40          45          50          55

tct ggg tca cca agt cct ccc cag agt cct gag ggt gcc tcc tct tcc      664
Ser Gly Ser Pro Ser Pro Gln Ser Pro Glu Gly Ala Ser Ser Ser
   60          65          70

ctg act gtc acc gac agc act ctg tgg agc caa tcc gat gag ggt tcc      712
Leu Thr Val Thr Asp Ser Thr Leu Trp Ser Gln Ser Asp Glu Gly Ser
   75          80          85

agc agc aat gaa gag gag ggg cca agc acc tcc ccg gac cca gct cac      760
Ser Ser Asn Glu Glu Gly Pro Ser Thr Ser Pro Asp Pro Ala His
   90          95          100

ctg gag tcc ctg ttc cgg gaa gca ctt gat gag aaa gtg gct gag tta      808
Leu Glu Ser Leu Phe Arg Glu Ala Leu Asp Glu Lys Val Ala Glu Leu
  105         110         115

gtt cgt ttc ctg ctc cgc aaa tat caa att aag gag ccg gtc aca aag      856
Val Arg Phe Leu Leu Arg Lys Tyr Gln Ile Lys Glu Pro Val Thr Lys
 120         125         130         135

gca gaa atg ctt gag agt gtc atc aaa aat tac aag aac cac ttt cct      904
Ala Glu Met Leu Glu Ser Val Ile Lys Asn Tyr Lys Asn His Phe Pro
 140         145         150

```

-11-

gat atc ttc agc aaa gcc tct gag tgc atg cag gtg atc ttt ggc att	952
Asp Ile Phe Ser Lys Ala Ser Glu Cys Met Gln Val Ile Phe Gly Ile	
155	160
	165
gat gtg aag gaa gtg gac cct gcc ggc cac tcc tac atc ctt gtc acc	1000
Asp Val Lys Glu Val Asp Pro Ala Gly His Ser Tyr Ile Leu Val Thr	
170	175
	180
tgc ctg ggc ctc tcc tat gat ggc ctg ctg ggt gat gat cag agt acg	1048
Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu Gly Asp Asp Gln Ser Thr	
185	190
	195
ccc aag acc ggc ctc ctg ata atc gtc ctg ggc atg atc tta atg gag	1096
Pro Lys Thr Gly Leu Leu Ile Ile Val Leu Gly Met Ile Leu Met Glu	
200	205
	210
	215
ggc agc cgc gcc ccg gag gag gca atc tgg gaa gca ttg agt gtg atg	1144
Gly Ser Arg Ala Pro Glu Glu Ala Ile Trp Glu Ala Leu Ser Val Met	
220	225
	230
ggg gct gta tgatggagg gggcacatg tctattggaa gctcaggaag	1193
Gly Ala Val	
ctgctcaccc aagagtgggt gcaggagaac tacctggagt accgccaggc gccccggcagt	1253
gatcctgtgc gctacgagtt cctgtgggtt ccaaggccc ttgctgaaac cagctatgtg	1313
aaagtccctgg agcatgtggt cagggtaat gcaagagttc gcatttccta cccatccctg	1373
catgaagagg ctttggaga ggagaaagga gttttagcag gagttgcagc tagggccagt	1433
ggggcaggtt gtggggaggc ctggggcagt gcacgttcca gggccacatc caccacttc	1493
cctgctctgt tacatgaggg ccattttca ctctgtgtt gaagagagca gtcacagttc	1553
ttagtagtg ggacatgtt ggggtgagg gaacacatg tggaccatct ctcagttcct	1613
gttctatgg gcgatttggaa ggttatctt tgtttcctt tggaaattgtt ccaatgttcc	1673
ttctaatttgg tgggtataatg aacttcaaca ttcattttat gtatgacagt agacagactt	1733
actgctttt atatagttt ggagtaagag tcttgctttt catttatact gggaaaccca	1793
tgttatttct tgaattc	1810

<210> 7
<211> 920
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (334)..(918)

<400> 7

acctgctcca ggacaaaatg gacccactg catcagctcc acctacccta ctgtcagtcc	60
tggagcccttgcctctgtccc gctgcatctt gaggagccat ctctcacttc cttttcagg	120
ttctcaggggg acagggagag caagaggtca agagctgtgg gacaccacag agcagcactg	180
aaggagaaga cctgttaagtt ggccttgtt agaacctcca ggggtgtggtt ctcaagctgtg	240
gccacttaca ccctccctct ctccccaggc ctgtgggtcc ccatcgcccc agtcctgccc	300

-12-

acactcccac	ctgctaccct	gatcagagtc	atc	atg	cct	cga	gct	cca	aag	cgt	354					
								Met	Pro	Arg	Ala	Pro	Lys	Arg		
								1				5				
cag	cgc	tgc	atg	cct	gaa	gaa	gat	ctt	caa	tcc	caa	agt	gag	aca	cag	402
Gln	Arg	Cys	Met	Pro	Glu	Glu	Asp	Leu	Gln	Ser	Gln	Ser	Glu	Thr	Gln	
								10		15		20				
ggc	ctc	gag	ggt	gca	cag	gct	ccc	ctg	gct	gtg	gag	gag	gat	gct	tca	450
Gly	Leu	Glu	Gly	Ala	Gln	Ala	Pro	Leu	Ala	Val	Glu	Glu	Asp	Ala	Ser	
								25		30		35				
tca	tcc	act	tcc	acc	agc	tcc	tct	ttt	cca	tcc	tct	ttt	ccc	tcc	tcc	498
Ser	Ser	Ser	Ser	Ser	Ser	Ser	Thr	Ser	Ser	Phe	Pro	Ser	Ser	Phe	Pro	Ser
								40		45		50		55		
tcc	tct	tcc	tcc	tcc	tcc	tcc	tgc	tat	cct	cta	ata	cca	agc	acc	cca	546
Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Cys	Tyr	Pro	Leu	Ile	Pro	Ser	Thr	Pro
								60		65		70				
gag	gag	gtt	tct	gct	gat	gat	gag	aca	cca	aat	cct	ccc	cag	agt	gct	594
Glu	Glu	Val	Ser	Ala	Asp	Asp	Glu	Thr	Pro	Asn	Pro	Pro	Gln	Ser	Ala	
								75		80		85				
cag	ata	gcc	tgc	tcc	ccc	tcg	gtc	gtt	gct	tcc	ctt	cca	tta	gat		642
Gln	Ile	Ala	Cys	Ser	Ser	Pro	Ser	Val	Val	Ala	Ser	Leu	Pro	Leu	Asp	
								90		95		100				
caa	tct	gat	gag	ggc	tcc	agc	agc	caa	aag	gag	gag	agt	cca	agc	acc	690
Gln	Ser	Asp	Glu	Gly	Ser	Ser	Ser	Gln	Lys	Glu	Glu	Ser	Pro	Ser	Thr	
								105		110		115				
cta	cag	gtc	ctg	cca	gac	agt	gag	tct	tta	ccc	aga	agt	gag	ata	gat	738
Leu	Gln	Val	Leu	Pro	Asp	Ser	Glu	Ser	Leu	Pro	Arg	Ser	Glu	Ile	Asp	
								120		125		130		135		
gaa	aag	gtg	act	gat	ttg	gtg	cag	ttt	ctg	ctc	ttc	aag	tat	caa	atg	786
Glu	Lys	Val	Thr	Asp	Leu	Val	Gln	Phe	Leu	Leu	Phe	Lys	Tyr	Gln	Met	
								140		145		150				
aag	gag	ccg	atc	aca	aag	gca	gaa	ata	ctg	gag	agt	gtc	ata	aaa	aat	834
Lys	Glu	Pro	Ile	Thr	Lys	Ala	Glu	Ile	Leu	Glu	Ser	Val	Ile	Lys	Asn	
								155		160		165				
tat	gaa	gac	cac	ttc	cct	ttg	ttg	ttt	agt	gaa	gcc	tcc	gag	tgc	atg	882
Tyr	Glu	Asp	His	Phe	Pro	Leu	Leu	Phe	Ser	Glu	Ala	Ser	Glu	Cys	Met	
								170		175		180				
ctg	ctg	gtc	ttt	ggc	att	gat	gta	aag	gaa	gtg	gat	cc				920
Leu	Leu	Val	Phe	Gly	Ile	Asp	Val	Lys	Glu	Val	Asp					
								185		190		195				

-13-

<210> 8
<211> 9
<212> PRT
<213> Homo sapiens

<400> 8
Glu Ala Asp Pro Thr Gly His Ser Tyr
1 5

<210> 9
<211> 9
<212> PRT
<213> Homo sapiens

<400> 9
Ser Ala Tyr Gly Glu Pro Arg Lys Leu
1 5

<210> 10
<211> 9
<212> PRT
<213> Homo sapiens

<400> 10
Glu Val Asp Pro Ile Gly His Leu Tyr
1 5

<210> 11
<211> 9
<212> PRT
<213> Homo sapiens

<400> 11
Phe Leu Trp Gly Pro Arg Ala Leu Val
1 5

<210> 12
<211> 10
<212> PRT
<213> Homo sapiens

<400> 12
Met Glu Val Asp Pro Ile Gly His Leu Tyr
1 5 10

<210> 13
<211> 9
<212> PRT
<213> Homo sapiens

-14-

<400> 13
Ala Ala Arg Ala Val Phe Leu Ala Leu
1 5

<210> 14
<211> 8
<212> PRT
<213> Homo sapiens

<400> 14
Tyr Arg Pro Arg Pro Arg Arg Tyr
1 5

<210> 15
<211> 10
<212> PRT
<213> Homo sapiens

<400> 15
Ser Pro Ser Ser Asn Arg Ile Arg Asn Thr
1 5 10

<210> 16
<211> 9
<212> PRT
<213> Homo sapiens

<400> 16
Val Leu Pro Asp Val Phe Ile Arg Cys
1 5

<210> 17
<211> 10
<212> PRT
<213> Homo sapiens

<400> 17
Val Leu Pro Asp Val Phe Ile Arg Cys Val
1 5 10

<210> 18
<211> 9
<212> PRT
<213> Homo sapiens

<400> 18
Glu Glu Lys Leu Ile Val Val Leu Phe
1 5

-15-

<210> 19
<211> 9
<212> PRT
<213> Homo sapiens

<400> 19
Glu Glu Lys Leu Ser Val Val Leu Phe
1 5

<210> 20
<211> 10
<212> PRT
<213> Homo sapiens

<400> 20
Ala Cys Asp Pro His Ser Gly His Phe Val
1 5 10

<210> 21
<211> 10
<212> PRT
<213> Homo sapiens

<400> 21
Ala Arg Asp Pro His Ser Gly His Phe Val
1 5 10

<210> 22
<211> 9
<212> PRT
<213> Homo sapiens

<400> 22
Ser Tyr Leu Asp Ser Gly Ile His Phe
1 5

<210> 23
<211> 9
<212> PRT
<213> Homo sapiens

<400> 23
Ser Tyr Leu Asp Ser Gly Ile His Ser
1 5

<210> 24
<211> 9

-16-

<212> PRT

<213> Homo sapiens

<400> 24

Met Leu Leu Ala Val Leu Tyr Cys Leu
1 5

<210> 25

<211> 9

<212> PRT

<213> Homo sapiens

<400> 25

Tyr Met Asn Gly Thr Met Ser Gln Val
1 5

<210> 26

<211> 9

<212> PRT

<213> Homo sapiens

<400> 26

Ala Phe Leu Pro Trp His Arg Leu Phe
1 5

<210> 27

<211> 9

<212> PRT

<213> Homo sapiens

<400> 27

Ser Glu Ile Trp Arg Asp Ile Asp Phe
1 5

<210> 28

<211> 9

<212> PRT

<213> Homo sapiens

<400> 28

Tyr Glu Ile Trp Arg Asp Ile Asp Phe
1 5

<210> 29

<211> 15

<212> PRT

<213> Homo sapiens

- 17 -

<400> 29
Gln Asn Ile Leu Leu Ser Asn Ala Pro Leu Gly Pro Gln Phe Pro
1 5 10 15

<210> 30
<211> 15
<212> PRT
<213> Homo sapiens

<400> 30
Asp Tyr Ser Tyr Leu Gln Asp Ser Asp Pro Asp Ser Phe Gln Asp
1 5 10 15

<210> 31
<211> 9
<212> PRT
<213> Homo sapiens

<400> 31
Ala Ala Gly Ile Gly Ile Leu Thr Val
1 5

<210> 32
<211> 10
<212> PRT
<213> Homo sapiens

<400> 32
Glu Ala Ala Gly Ile Gly Ile Leu Thr Val
1 5 10

<210> 33
<211> 9
<212> PRT
<213> Homo sapiens

<400> 33
Ile Leu Thr Val Ile Leu Gly Val Leu
1 5

<210> 34
<211> 9
<212> PRT
<213> Homo sapiens

<400> 34
Lys Thr Trp Gly Gln Tyr Trp Gln Val
1 5

-18-

<210> 35
<211> 9
<212> PRT
<213> Homo sapiens

<400> 35
Ile Thr Asp Gln Val Pro Phe Ser Val
1 5

<210> 36
<211> 9
<212> PRT
<213> Homo sapiens

<400> 36
Tyr Leu Glu Pro Gly Pro Val Thr Ala
1 5

<210> 37
<211> 10
<212> PRT
<213> Homo sapiens

<400> 37
Leu Leu Asp Gly Thr Ala Thr Leu Arg Leu
1 5 10

<210> 38
<211> 10
<212> PRT
<213> Homo sapiens

<400> 38
Val Leu Tyr Arg Tyr Gly Ser Phe Ser Val
1 5 10

<210> 39
<211> 9
<212> PRT
<213> Homo sapiens

<400> 39
Leu Tyr Val Asp Ser Leu Phe Phe Leu
1 5

<210> 40
<211> 12
<212> PRT

-19-

<213> Homo sapiens

<400> 40
Lys Ile Ser Gly Gly Pro Arg Ile Ser Tyr Pro Leu
1 5 10

<210> 41

<211> 9

<212> PRT

<213> Homo sapiens

<400> 41
Tyr Met Asp Gly Thr Met Ser Gln Val
1 5

<210> 42

<211> 9

<212> PRT

<213> Homo sapiens

<400> 42

Gly Leu Tyr Asp Gly Met Glu His Leu
1 5

<210> 43

<211> 9

<212> PRT

<213> Homo sapiens

<400> 43

Gly Leu Tyr Asp Gly Arg Glu His Ser
1 5

<210> 44

<211> 10

<212> PRT

<213> Homo sapiens

<400> 44

Gly Leu Tyr Asp Gly Met Glu His Leu Ile
1 5 10

<210> 45

<211> 10

<212> PRT

<213> Homo sapiens

-20-

<400> 45
Gly Leu Tyr Asp Gly Arg Glu His Ser Val
1 5 10

<210> 46
<211> 9
<212> PRT
<213> Homo sapiens

<400> 46
Met Leu Leu Val Phe Gly Ile Asp Val
1 5

<210> 47
<211> 10
<212> PRT
<213> Homo sapiens

<400> 47
Cys Met Leu Leu Val Phe Gly Ile Asp Val
1 5 10

<210> 48
<211> 9
<212> PRT
<213> Homo sapiens

<400> 48
Phe Leu Leu Phe Lys Tyr Gln Met Lys
1 5

<210> 49
<211> 9
<212> PRT
<213> Homo sapiens

<400> 49
Phe Ile Glu Gly Tyr Cys Thr Pro Glu
1 5

<210> 50
<211> 9
<212> PRT
<213> Homo sapiens

<400> 50
Gly Leu Glu Leu Ala Gln Ala Pro Leu
1 5

-21-

<210> 51
<211> 29
<212> DNA
<213> Homo sapiens

<400> 51
ggaattcatacgatgcctcgag ctccaaagc 29

<210> 52
<211> 31
<212> DNA
<213> Homo sapiens

<400> 52
gctcttagagc tttaggctatcg tgagactct g 31

<210> 53
<211> 31
<212> DNA
<213> Homo sapiens

<400> 53
gctcttagagc tttagcactcg gaggttacac t 31

<210> 54
<211> 31
<212> DNA
<213> Homo sapiens

<400> 54
gctcttagagc ttaccaatct tgggtgagca g 31

<210> 55
<211> 21
<212> DNA
<213> Homo sapiens

<400> 55
cacagagcag cactgaaggag 21

<210> 56
<211> 23
<212> DNA
<213> Homo sapiens

<400> 56
ctgggtaaag actcactgtc tgg 23